Differentiation of Cells Isolated from Afterbirth Tissues into Hepatocyte-Like Cells and Their Potential Clinical Application in Liver Regeneration

Marcin Michalik1 · Aleksandra Gładys1 · Piotr Czekaj1

Accepted: 16 September 2020 / Published online: 25 September 2020
© The Author(s) 2020

Abstract
Toxic, viral and surgical injuries can pose medical indications for liver transplantation. The number of patients waiting for a liver transplant still increases, but the number of organ donors is insufficient. Hepatocyte transplantation was suggested as a promising alternative to liver transplantation, however, this method has some significant limitations. Currently, afterbirth tissues seem to be an interesting source of cells for the regenerative medicine, because of their unique biological and immunological properties. It has been proven in experimental animal models, that the native stem cells, and to a greater extent, hepatocyte-like cells derived from them and transplanted, can accelerate regenerative processes and restore organ functioning. The effective protocol for obtaining functional mature hepatocytes in vitro is still not defined, but some studies resulted in obtaining functionally active hepatocyte-like cells. In this review, we focused on human stem cells isolated from placenta and umbilical cord, as potent precursors of hepatocyte-like cells for regenerative medicine. We summarized the results of preclinical and clinical studies dealing with the introduction of epithelial and mesenchymal stem cells of the afterbirth origin to the liver failure therapy. It was concluded that the use of native afterbirth epithelial and mesenchymal cells in the treatment of liver failure could support liver function and regeneration. This effect would be enhanced by the use of hepatocyte-like cells obtained from placental and/or umbilical stem cells.

Keywords Afterbirth cells · Differentiation · Hepatocytes · Liver failure · Cell transplantation

Introduction
The number of patients waiting for a liver transplant increases every year. This is caused, among other reasons, by clinically justified transplant indications and insufficient number of organ donors. As a consequence, the waiting time for the transplantation is getting longer, leading to a shorter transplant functioning time, and lower patient survival rate [1]. Another unfavorable prognostic phenomenon is an increase in donors' age, resulting in transplantation of organs with a shorter expected functioning time [2]. A partial solution for the growing demand for liver transplantations was the introduction of a ‘split’ procedure, in which two parts of the graft are separated: left lateral segment graft and right extended liver lobe graft. Due to this procedure, it is possible to partially meet the demand and also to obtain the transplants of reduced volume for pediatric recipients [3]. Another promising alternative to the whole organ transplantation procedure is the hepatocyte transplantation. It is currently being evaluated in some clinical trials, where hepatocytes are transplanted to patients with hepatic failure, thus restoring their population [4]. However, the use of this method is very limited. Among the limitations are: difficulties with obtaining high-quality hepatocytes, insufficient colonization of the liver by transplanted cells (in particular in case of cirrhosis), and the lack of reliable data describing a long-term effect. Currently, there are only two clear indications for this procedure: inborn errors of metabolism such as Crigler-Najjar syndrome, and acute liver damage [5].

The growing demand for liver transplantation, caused by its failure and/or the need to maintain its function until
the transplantation procedure, is a strong stimulus to look for alternative therapies, such as the stem cell therapy. Afterbirth tissues, i.e. placenta and umbilical cord are abundant sources of cells, that meet the biological criteria of good transplantable material, and can be isolated in a manner that does not raise moral and ethical controversies. Some of afterbirth cell populations are successfully used in clinical trials, including the treatment of type 1 diabetes, systemic lupus erythematosus and ischemic stroke [6–11]. Both in vivo and in vitro studies have shown that cells derived from these sources, e.g. amniotic epithelial cells, have potential for proliferation and differentiation, and show some efficacy in the treatment of liver failure. The use of amniotic cells in therapy of hepatic failure in animal models resulted in organ functioning improvement. Positive effect of human amnion cells (hAC) was observed in case of acquired failure caused by chemical damage and also in congenital failure caused by inborn errors of metabolism [12]. The expression profile of surface antigens enables the use of these cells in treatment of liver failure in humans without the need for immunosuppression, since they are characterized by the lack of expression of class II histocompatibility antigens. They express the CD47 antigen responsible for "don't eat me signal", and also complement antigen complex CD44/CD59 [13]. It seems that the positive effect is greater, when the used cells are close to the mature hepatocytes [14]. Therefore, the preliminary ex vivo differentiation of stem cells may be crucial for the effectiveness of the therapy of damaged organ applied resulting in its in vivo regeneration.

Liver Development and Regeneration

The mature liver has considerable capacity for spontaneous regeneration. Several cell populations participate in this process. These are mainly hepatocytes, but also multiple multipotent and bipotent stem cell populations expressing endodermal or mesenchymal markers [15–20].

In the process of liver regeneration, the sequence of cellular changes refers to changes occurring during its embryonic development. Models of liver development are comparable among mammal species, including mice, rats, and humans [21]. In mice, hepatoblast differentiation to hepatocytes occurs between the 14th and 16th day of embryo development. In humans, this process begins around 56-58 days of pregnancy and ends around day 210 [22].

In the developing liver, there is a continuous cross-talk between endodermal, mesendodermal, and mesenchymal cells, as a result of direct action as well as paracrine signaling. These populations also stimulate hematopoietic cells inhabiting the fetal liver [17]. Liver stem cells, hepatic stellate (Ito) cells, endothelial cells, and presumably mesenchymal cells secrete growth factors stimulating hepatoblasts to proliferate and differentiate into hepatocytes or cholangiocytes [23]. At early stages of embryonic development, hepatogenesis depends on such factors, as FGF (fibroblast growth factor), BMP (bone morphogenetic protein), WNT [24], HGF (hepatocyte growth factor), MAPK9 (mitogen-activated protein kinase 9) and TGFβ (transforming growth factor β) [25]. At later stages of the prenatal period, liver development depends more on HGF-related signaling pathways, but also on insulin, cAMP (cyclic adenosine monophosphate), TGFr (transforming growth factor α), PI3K (phosphatidylinositol-3 kinase), mTOR (mechanistic target of rapamycin) and MAPK/ERK kinases [26].

Human hepatic stem cells (hHpSC) seem to be the primary population of cells with the greatest potential of proliferation and differentiation in the hepatic direction. hHpSC have been characterized as multipotent precursors to fetal hepatic progenitor cells - hepatoblasts, located in ductal plates in fetal and neonatal livers, and also in the canals of Hering in adult livers of all donor ages [27].

A population of cells with a similar or perhaps identical phenotype to the hHpSCs are biliary tree stem/progenitor cells (BTSC). BTSC are multipotent stem cells located in peribiliary glands of large intrahepatic and extrahepatic bile ducts and can be differentiated into hepatic and pancreatic lineages [28, 29]. BTSC populations are characterized by the expression of classic endodermal transcription factors: FOXA2, HNF6 (hepatic nuclear factor 6), PROX1, SLL4, SOX9, SOX17, and markers specific for endodermal progenitors: EpCAM (epithelial cell adhesion molecule), NCAM (neural cell adhesion molecule), CD133, and CXCXR4. They are negative or express low levels of hepatic markers: AFP (alpha-fetoprotein), ALB (albumin), GGT (gamma-glutamyl transferase) and endocrine pancreas (insulin, glucagon), as well as mesenchymal, endothelial, and hematopoietic markers [29]. BTSC are available from all age donors and it was suggested that they may be involved in the regeneration of the liver, pancreas, and bile ducts [28].

Human hHpSC and hepatoblasts overlap in their phenotypic markers (Table 1) with prominent participation of EpCAM. EpCAM (CD326) is a multifunctional transmembrane protein that is mainly involved in intercellular adhesion. In neoplastic cells and cancer stem cells, it participates in mediating the signal for proliferation and maintaining the stem-like character of cells [30]. However, during the differentiation of hHpSC into hepatoblasts, the expression of EpCAM on their surface decreases. At the same time, on the surface of hepatoblasts the expression of NCAM (CD56) completely disappears, and it is replaced by ICAM-1 (intercellular adhesion molecule 1, CD54). Moreover, the expression of AFP, CD133, and some other markers, increases [24, 27, 31, 32]. Along with the progress of stem cell differentiation into hepatoblast, the enhanced expression of AFP, albumin, and fetal P450 isoenzymes, eg. CYP3A7, was noted in mice [33]. On the other hand, hHpSC...
and hepatoblasts do not express markers specific for adult hepatic progenitor cells (HPC), also known in rodents as oval cells, eg. CD34 and CD117 [27, 34].

The roles of the various markers associated with liver stem and progenitor potential for differentiation was confirmed in the iPSC-based model of liver development. Elevated expression of EpCAM and HNF4-α (as well as GATA4, claudin, and NCAM) was observed in early hepatic differentiation, at the stage of hepatic stem cell right after definitive endoderm, while increased expression of AFP and CD133, as well as ICAM1, CK19 (cytokeratin 19), and SOX9 was specific for a later stage of hepatoblast-like hepatic progenitors [24].

Hepatoblasts are defined as bipotent and give rise to liver precursors for hepatocyte or cholangiocyte cell lines. Process of hepatoblast maturation is associated with changes in the expression profile of many transcription factors [25]. Mature hepatocytes are entirely negative for progenitor markers such as EpCAM, AFP, and Dlk1 (delta-like 1 homolog). In contrast, during differentiation the expression of proteins specific for mature liver, such as albumin, alpha-1 antitrypsin (A1AT), cytokeratin 18, cytochrome P450, transferrin, and tyrosine aminotransferase (TAT), increases. Moreover, these matured cells acquire the ability to synthesize and store glycogen [24]. A similar phenomenon of the loss of progenitor cell markers occurs during hepatoblasts differentiation into cholangiocytes. As a result, mature bile duct epithelial cells become positive for markers such as CK7, CK19, osteopontin, GGT and CFTR [39, 40].

Attempts to use human liver fetal cells in clinical trials have shown their safety and long-term effect in the treatment of liver cirrhosis of various etiologies, resulting in the improvement of organ function expressed by a decrease in MELD score [41]. However, the cells used in this clinical trial did not represent a homogeneous hepatoblast population. Patients received an isolated mixture of cells consisting of hepatocytes, hematopoietic and mesenchymal cell lines, expressing such markers as vimentin, CD90, and CD29. Therefore, it is not possible to give an unambiguous answer whether human hepatoblasts support adult liver regeneration in humans, or it may be the consequence of an action of other liver stem/progenitor populations. Moreover, it should be taken into consideration that the main limitation in the use of fetal liver stem cells in the treatment of liver failure on a large scale is the ethical controversy related to obtaining these cells from human fetuses.

Table 1 Human hepatic stem cells (hHpSC) and hepatoblasts

| Positive markers | Negative markers | Ref. |
|------------------|------------------|-----|
| Human hepatic stem cells | EpCAM, NCAM, CD44H, CD133, CK8/18/19, claudin-3, CXCR4, FOX2, SOX9, SOX17, telomerase, ALB (weak or negligible) | ICAM1, AFP, CD45, CYP450, desmin, VEGFr | [27, 35] |
| Hepatoblasts | EpCAM, ICAM-1, AFP, ALB, CD29, CD44H, CD133, CK8, CK19, CYP3A7, DLK1 | NCAM, α-SMA, CD14, CD34, CD38, CD45, CD90, CD146, CYP3A4, desmin | [17, 27, 35] |
| | EpCAM, AFP, ALB, DLK1, GPC3 | NCAM, CD45, CD235a, CK7 | [36] |
| | EpCAM, CD26, CD49f, CD324, CK18, CK19 | CD34, CD45, CD133 | [37] |
| | EpCAM, ICAM-1, AFP, ALB, CK8, CK18, CK19, CYP3A7, IH, PTC1, SHH, SOX-9, SOX-17 | CD34, CD45 | [31] |
| | EpCAM, ICAM-1, AFP, ALB, CK8, CK18, CK19 | NCAM, CD31, CD34, CD38, CD45, CD90, CD105, CD146, claudin-3, CYP3A4, desmin, VEGFr | [38] |

hHpSC are multipotent and self-renewing precursors for bipotent prenatal hepatoblasts giving rise to mature hepatocytes and cholangiocytes, as well as to other endodermal cell types. hHpSC, hepatoblasts, and most cholangiocytes express EpCAM, whereas mature hepatocytes are EpCAM- . Both hHpSC and hepatoblasts do not express hematopoietic, endothelial or mesenchymal markers. In general, they are different from each other in that hHpSC are NCAM+/ICAM1-/AFP- , while hepatoblasts are NCAM-/ICAM1+/AFP+ .

Abbreviations: α-SMA α-smooth muscle actin, IH Indian hedgehog, SHH Sonic hedgehog.
liver cells pass from the G1 to M phase [42]. The regeneration phase is maintained and stimulated by direct and indirect growth factors [44]. The most important direct factors promoting this process are ligands for EGFR (epidermal growth factor receptor), namely HGF, EGF, TGFα and HB-EGF; FGF (fibroblast growth factor) and its receptors, as well as Ras-MAPK and PI3K/ACT pathways [42]. Mentioned above, direct factors promote mitosis of hepatocytes in vitro and in vivo. Among the auxiliary factors involved in liver regeneration and differentiation of hepatocytes are: bile acids, estrogens, IGF-1 (insulin-like growth factor 1), insulin, TNFα and TNFR1 (tumor necrosis factor receptor 1), IL-6, STAT3, norepinephrine, FXR receptor, TFR5 receptor, VEGF (vascular endothelial growth factor), as well as Wnt/β-catenin and Hedgehog signaling pathways [43]. Auxiliary factors do not stimulate the divisions of mature hepatocytes, but they intensify and accelerate the action of direct factors [45].

After partial hepatectomy, the liver is able to restore a significant part of its original volume (in rat liver, up to 70% of its mass may be restored) as a result of the proliferation of hepatocytes, bile duct epithelium, Kupffer cells, endothelial cells, Ito cells and fibroblasts [46, 47]. This proliferation, however, occurs not due to mechanical damage, but it is a reaction to a decrease in organ size [46]. It is known that after partial hepatectomy, human liver regenerates within 3-12 months, and the rate of regeneration is proportional to the volume of the resected fragment [48]. In the study of healthy living donors’ livers, their liver volume after right-sided hemihepatectomy increased by 94% after seven days (liver volume after surgery was 35% of the original volume), while in patients after left lateral sectionectomy the volume increased by 22% seven days after surgery (with a postoperative volume of 81% of the original one) [49]. The mechanisms for maintaining a constant liver mass have been termed “hepatostat” [46, 50, 51]. Despite restoring normal cell numbers and organ weight, the amount of liver lobules is not increased [51]. Stoppage of regenerative processes occurs mainly through the Yap protein associated with the Hippo pathway, and pathways associated with the integrin α3/β1 [43].

It is generally accepted that liver regeneration after partial hepatectomy is mediated by hepatocytes, however in the chronic liver diseases of various etiologies the regenerative potential of hepatocytes is limited, and multipotent or bipotent resident stem/progenitor cells are activated.

Multipotent hepatic stem cells can be isolated from both healthy and diseased adult human livers [52]. They are characterized by the expression of mesenchymal markers, as well as some hepatocytic, cholangiocytic and neuronal markers, integrins and adhesion molecules (Table 2). There are only few studies confirming expression of pluripotent markers in these cells. In turn, they do not express hematopoietic and endothelial markers [53, 54].

In vitro culture stem cells expressing mesenchymal markers have spindle-shaped morphology resembling that of mesenchymal stem cells (MSC) isolated from other human tissues. Their location within the liver parenchyma is not precisely determined, and an origin is not known. It was hypothesised that these stem cells are the descendants of resident MSC persisting in the liver, circulating MSC or bone marrow mesenchymal stem cells (BM-MSC), hepatic pericytes or Ito cells, or dedifferentiated hepatocytes by the process of epithelial-to-mesenchymal transition [15].

In vitro liver mesenchymal stem cells divide intensively reaching the confluence required for passage after about 3-5 days of culture. They are able to differentiate in vitro not only towards the hepatocytic lineage [52, 59, 60, 64, 65], but also osteogenic [52, 59, 65], chondrogenic [61], endothelial [52, 53] lineages, and insulin-producing islet cells of the pancreas [52, 56], but not to the adipocytic lineage [52, 59, 61]. On the other hand, one study demonstrated that liver mesenchymal stem cells are able the differentiate into adipocyte-like cells [65]. Following intrasplenic administration to mice, hepatic stem cells were localized in the liver and differentiated into hepatocytes in vivo, thus acquiring the ability to synthesize albumin [64].

The therapeutic potential of human liver stem cells and extracellular vesicles (EVs) derived from these cells has been reported in numerous preclinical animal trials, and subsequently also in human clinical trials. Preclinical trials with the use of human liver stem-like cells (HLSC) revealed increased survival of mice with Crigler-Najjar syndrome type 1 [60] and acute liver failure [52, 55], and alleviated the symptoms of nonalcoholic fatty liver disease in mice [57, 68]. Moreover, HLSC improved the function of acutely damaged kidneys of various etiologies [69]. Animal models showed the protective effect of HLSC-EVs in chronic kidney disease and the lower expression of genes responsible for kidney fibrosis [70]. EVs reduced liver damage in a mouse model of liver injury associated with hepatic perfusion disorders [71] and reversed kidney damage in mice with diabetic nephropathy [72]. The therapeutic potential of HLSC-EVs was demonstrated also in cancer cell research. When applied in vivo to mice, HLSC-EVs influenced human kidney cancer cells by reducing their activity, inducing apoptosis and inhibiting proliferation. Furthermore, by reducing the degree of tumor vascularization, the EVs increased the time needed to the occurrence of metastases [58, 73, 74].

Successful preclinical trials of the use of HLSC in cell therapy resulted in their admission to the first phase of clinical trials in a study of metabolic hyperammonemia in children. The results confirmed the safety of HLSC administration to humans. No significant negative side effects were observed, and no need for immunosuppression was demonstrated [59].
### Table 2  Phenotypic characteristics of adult-derived human liver multipotent stem cells expressing typical mesenchymal markers

| Original cell name | Positive markers | Negative markers | Hepatogenic differentiation | Differentiation potential | Ref. |
|--------------------|------------------|------------------|----------------------------|---------------------------|------|
| Human liver stem-like cells (HLSC) | **Mesenchymal:** CD44, CD73, CD90, CD105 (20%), CD146 (18%), vimentin **Other:** AFP, ALB, CD29, CD31, CK8 (11-30%), CK18 (15-30%), HLA-A, HLA-G, Musashi1, NANOG, nestin, Oct-4, Pax2, Sox2, SSEA4 | **Mesenchymal:** α-SMA, STRO-1 **Other:** CD14, CD31, CD34, CD45, CD117, CD133, CK19, cytochrome P450, NCAM | Rotary Cell Culture System; DMEM low glucose, 40% MCDM-201, 1x ITS, 1x L-arginine 2-phosphate, 10^{-5} M dexamethasone, 10^{-3} acetic acid 2-phosphate, 10 ng/ml HGF, 10 ng/ml FGF-4, 2% FBS or Rat Liver Cell Culture System; α-MEM/EBM 3:1, 12 mM Hepes, 2% FCS, 10 ng/ml HGF, 10 ng/ml FGF-4 or rat liver acellular scaffolds recellurized with HLSC in standard medium or with 10 ng/ml EGF and 10 ng/ml FGF-4, or with HLSC-derived conditioned medium | hepatogenic, osteogenic, endothelial, insulin-producing islet-like structures no adipogenic potential | [52–60] |
| Adult-derived human liver mesenchymal-like cells (ADHLSC) | **Mesenchymal:** CD73, CD90, vimentin **Other:** ALB, CD29, CD49b (32%), CD49e (31%), HLA-A1; at mRNA level: A1AT,AFP,CYP1B1, CYP3A4, G6P, GGT, GS,HNF-4α, MRP2 | **Mesenchymal:** CD105 **Other:** CD49f (19%), CD34, CD45, CD117, CD133, CK7, CK8, CK18, CK19, CYP2B6, HLA-II, Oct-4, TAT, TDO | 1st step: IMDM, 20 ng/ml HGF, 10 ng/ml FGF-4, 0.61 g/L nicotinamide, 1% ITS (10 days) 2nd step: IMDM, 20 ng/ml oncostatin M, 1 μM dexamethasone, 1% ITS (10 days) | hepatogenic no osteogenic or adipogenic potential | [61–63] |
| Liver-derived mesenchymal stem cells (L-MSCs) | **Mesenchymal:** CD90, CD105, CD167 **Other:** CK19, HGF | ALB, CD34, CD45, CK18, c-Met, HLA-II | 1st step: IMDM with 20 ng/ml FGF, 10 ng/ml FGF-2 (2 days) 2nd step: IMDM with 20 ng/ml HGF, 10 ng/ml LIF, 0.61 g/L nicotinamide, 1% ITS (10 days) 3rd step: incubation with infectious Japanese fulminating hepatitis 1 (FH1)-derived hepatitis C virus (HCV) particles (10 days) | hepatogenic, adipogenic, osteogenic | [65] |
| Liver Mesenchymal Stem Cells/Liver Stromal Cells | **Mesenchymal:** CD44 (30%), CD90 (30%) **Other:** CD166 (10-25%), CD227 (10-25%), c-Met (50%) | CD34, CD45, CD91, EpCAM | 1st step: DMEM/F12, 2 mM Glutamax, 0.5% FBS, 10 ng/ml HGF, 100 ng/ml Activin A (10 days) 2nd step: DMEM/F12, 2 mM Glutamax, 15 mM HEPS, 2 μg/ml insulin, 10 ng/ml FGF-4, 10 ng/ml HGF, 10 ng/ml oncostatin M, 10^{-7} M dexamethasone (10 days) | hepatogenic | [15, 66, 67] |

One exception is CD105 which expression was shown to be low or absent in some studies. Liver mesenchymal stem cells do not express hematopoietic and endothelial markers, and are different from bipotent hepatic progenitor cells (HPC).

**Abbreviations:** GS glutamine synthase, ITS insulin, transferrin and selenious acid, MRP2 multidrug resistance protein-2, TDO tryptophan 2,3-dioxygenase, HLA human leukocyte antigen.
Several human clinical trials using HLSC are currently ongoing. Attempts are being made to use them in various liver diseases: congenital, as well as acquired, such as chronic liver failure or NASH (NCT03884959, NCT02946554, NCT03963921, NCT01765283) [75].

Human bipotent hepatic progenitor cells (HPC) are often referred to as oval cells due to their shape in rodents livers. HPC are quiescent in healthy liver and become precursors of hepatocytes and cholangiocytes in injured liver [76, 77]. This is a reason that many markers of HPC are only expressed in the liver after chemical or viral injury, when these facultative progenitor cells are activated. The number of HPC correlates with the severity of liver disease [78].

Oval cells/HPC are located in the wall of canals of Hering in periportal areas. Proliferation and differentiation of oval cells was observed in rat and mouse models of chronic liver injury in which hepatocyte proliferation is inhibited. HPC expand in human chronic liver diseases, mainly chronic inflammations of various etiologies and tumorigenesis [79–81]. In humans, a minimum 50% hepatocyte loss is required for significant activation of the HPC compartment [78]. Wnt pathway plays a significant role in HPC expansion, while the Notch pathway is involved in the HPC differentiation towards the cholangiocyctic lineage [82].

The process of the liver regeneration dependent on oval cells/HPC is often referred to as ductal reaction. Besides its activation, ductal reaction also includes immune cell infiltration, Ito cells activation and remodeling of the extracellular matrix - ECM [83]. In a damaged liver, Kupffer cells secrete pro-inflammatory cytokines such as TNFα and IL-6 in response to complement activation or under the influence of the superantigen - LPS (lipopolysaccharide). These ligands, by connecting with their IL-6R and TNFR1 receptors on progenitor cells, stimulate their proliferation [84], and lead to activation of MAPK and PI3K/AKT signaling pathways [42] involved, among others, in hepatic differentiation [84, 85]. Progenitor cells proliferate and then migrate to Disse's space or even liver parenchyma [86], where they differentiate into hepatocytes or cholangiocytes [87]. Concentration of proinflammatory cytokines including INFγ (Interferon-gamma), increases in damaged liver parenchyma. Inflammatory cytokines stimulate M1 macrophages to secrete pro-inflammatory and profibrotic cytokines. In contrast, M2 cells secrete IL-4 and IL-13 factors, that inhibit the inflammatory response and participate in extracellular matrix degradation [88].

The cellular origin of heterogenous population of HPC is still not clarified. The relationship between HPC that appear in the adult liver and fetally derived hHpSC remains unresolved. In turn, based on the comparison of HPC and fetal hepatoblasts, which both are proliferating, clonogenic, bipotential, and share the same markers such as Dlk-1, and alpha-fetoprotein, as well as are able to repopulate in vivo, it has been suggested that hepatoblasts are precursors to HPC. On the other hand, in some studies the cells expressing Dlk-1 and AFP have not been observed in the healthy, uninjured liver, what argues against the relationship between fetal hepatoblast and adult HPC [78]. Furthermore, HPC differ phenotypically and functionally from human liver multipotent stem cells expressing mesenchymal markers [52, 59]. These contradictory findings regarding the origin of HPC may also suggest their multiple maturation stages [38, 78].

A pattern of specific markers for HPC determined in patients with chronic liver injury or submassive hepatic necrosis was shown to be similar to those of rodent oval cells. Commonly used markers for the identification of oval cells in rodents are, among others: adult hepatocyte markers (A1AT, ALB, CK8, CK18, HNF4), hepatoblast markers (AFP, CD26, CD29, CD49f, GGT, MPK, and some other), cholangiocyte markers (A6 antigen, CD133, C-met, CK7, CK19, EpCAM, OV-1, OV-6), hematopoetic markers (CD34, c-Kit, CXCR4, Thy-1), and neuroepithelial markers as chromogranin A. Besides, on their surface, there are receptors for HGF, EGF, and TNFα, which are involved in signal transmission to proliferate and differentiate [22, 76, 77]. A distinct pattern of HPC surface markers was found between acute and chronic liver diseases [89]. Most of the molecular markers for oval cells are also expressed in cholangiocytes [76]. As a consequence, there are no specific markers to differentiate HPC from cholangiocytes and the application of the above markers seems to be limited by their lack of cell-type specificity [83].

The application of HPC to cell therapy is an attractive solution, because HPC can be isolated even from diseased livers, expanded in culture without losing its bidirectional differentiation potential, and transplanted back to the patient without the need for immunosuppression [78]. Unfortunately, the efficiency of HPC repopulation and engraftment is still relatively low compared to primary hepatocyte transplantation. Current protocols fail to differentiate HPC into fully mature hepatocytes in culture, and it is not known whether HPC can be tumorigenic in the recipient [78, 83].

It should be taken into consideration that the thesis that facultative liver stem cells are an important source of new hepatocytes and cholangiocytes in chronically injured liver is being challenged [16, 90–92]. It cannot be excluded that also the plasticity of both hepatocytes and cholangiocytes can account for tissue repair in the liver and biliary regeneration, including highly replicative hepatocyte subpopulations, hybrid hepatocytes, hepatocytes characterized by high expression of telomerase, as well as so-called small cholangiocytes. Finally, transdifferentiation of both hepatocytes and cholangiocytes into the other compartment when one compartment is significantly damaged was observed [83, 93]. It
also was suggested that hepatocytes can dedifferentiate into HPC in response to liver injury [78].

As in many other cells with a stemness potential, the activation of hepatoprogenitors carries the risk of neoplastic transformation, that gives rise to an immortal cell line [77]. However, the regenerating liver has inhibitory mechanisms necessary to avoid excessive proliferation resulting in neoplasia. Inhibitory factors include TGFβ and - belonging to the same family: BMP and Activin A. The inhibitory effect of TGFβ on hepatocyte proliferation is balanced by the profibrotic effects of Activin A and Activin B, as well as BMPs. At high concentrations, profibrotic factors from the TGFβ family affect Ito cells and stimulate them to transform into myofibroblasts, which results in increased liver fibrosis, cirrhosis and hepatocyte death [94]. Activin A often appears as a supplement in hepatocyte differentiating media, despite its proven proapoptotic properties against hepatocytes [95].

### Differentiation of Afterbirth Cells Towards Hepatocytes

To date, a number of attempts have been made to differentiate stem cells into hepatocytes, with the intention of using them in organ regeneration. Some satisfactory results have been obtained in in vitro differentiation of cells such as human embryonic stem cells (hESC) [96, 97], human dental pulp stem cells (hDPSC) [98, 99] and bone marrow mesenchymal stem cells [100–102], as well as placental and umbilical cord stem cells (Tables 3, 4 and 5).

### Characteristics of Human Epithelial and Mesenchymal Afterbirth Cells

Human amniotic membrane is a source of both: epithelial (hAEC; human amniotic epithelial cells), and mesenchymal

---

### Table 3

Protocols for in vitro hAEC differentiation towards hepatocytes, ordered by culture time. Observed changes in gene and protein expression are included.

| Culture time & surface | Differentiating medium | Gene up-regulation | Gene down-regulation | Protein expression | Cell activity | Ref. |
|------------------------|------------------------|--------------------|----------------------|--------------------|--------------|------|
| 14 days Matrigel       | IMDM, 10% Fetal bovine serum (FBS), 100 mM non-essential amino acids (NEAA), 2 mM L-glutamine, 10 ng/ml EGF, 10 ng/ml KGF, 20 ng/ml HGF, 1 μM dexamethasone (dex), 20 ng/ml oncostatin M (OSM), 55 μM β-mercaptoethanol, 1% ITS Premix | A1AT, AFP, ALB, CK19, CYP: 1A2, 2B6, 3A4, 7A1 | NANOG, OCT-4, SSEA4 | ALB | Indocyanine green uptake, glycogen storage, albumin and urea secretion | [113] |
| 18 days plastic        | DMEM/B27, 10ng/mL FGF2, 20ng/ml HGF, 100ng/ml Activin A, 20ng/ml OSM, 100μM/L Sodium Taurocholate Hydrate, 20ng/ml BMP4 | AFP, CYP7A1, FOXA1, TAT | OCT-4 | A1AT, ALB, HNF-4α | Indocyanine green and LDL uptake, CYP450 inducible activity | [14] |
| 20 days Collagen type I| DMEM/IDMEM, 10% FBS, 20ng/ml EGF, 10 M dex, 100ng/ml Activin A, 0.5% m Hu-alb (Human albumin) | A1AT, ALB, CAR, C/EBPa, C/EBPθ, CK8, CK18, CK19, c-MET, CYP: 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, 3A7, 7A1, HNF-1α, HNF-4α, OATP, PPAR, PRX, RAR, RXR, | BRCP, OCT-4 | Not given | Not given | [114] |
| ~21 days L-ECM         | DMEM, 5% FBS, 10ng/ml EGF, 10ng/ml FGF2, 10ng/ml HGF, 10 → 5 M dex, 100ng/ml Activin A | ALB, CYP: 2B6, 2D6, 3A4, 3A7, UGT1A1 | Not given | ALB, CYP2E1, CYP3A1 | Ammonia metabolism, CYP450 inducible activity | [115] |
| ~28 days plastic       | DMEM, 10% FBS, 1 mM NEAA, 4 mM L-glutamine, 10 ng/ml EGF, 0.1 μM dex, 1 mM pyruvate | A1AT, ALB, AFP, CCND1, CYP7A1 | NANOG, OCT-4, P21, P53, SOX-2 | CYP3A4, CYP7A1 | Increased ERK 1/2 phosphorylation | [85] |
| ~35 days Collagen type I| DMEM/F12, 10% FBS, 10ng/ml EGF, FGF-4, HGF, 0,1μM dex, 10% HepG2 cell-conditioned medium, 0,1μM insulin | ABCA2, ABCB11, AS1, CYP3A4, CYP7A1 | EPHX1, SLC27A | ALB, HNF-4α | LDL and glycogen presence, Indocyanine green uptake, urea synthesis | [116] |
cells (hAM-MSC; human amniotic mesenchymal stromal cells). Population of epithelial cells can be obtained as a result of trypsinization of the amniotic membrane [103–106]. A part of hAEC has surface markers of pluripotency, such as SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and is characterized by the expression of the \textit{OCT4}, \textit{KLF4}, \textit{REX1} genes [107, 108]. hAEC originate from the epiblast, which gives rise to three germ layers. This means, that isolated amnion epithelial cells can potentially give rise to tissues derived from all germ layers. The observed features of pluripotency make amnion epithelial cells similar to hESC. Furthermore, for ethical reasons and because of their biological properties, hAEC are an interesting alternative to embryonic cells in regenerative medicine. In contrast to hESC (or induced pluripotent stem cells - iPSC), they have low expression of MHC-I (major histocompatibility complex-I) antigens, and they lack MHC-II (major histocompatibility complex-II) antigens, what eliminates the possibility of inducing the recipient's immune system response. hAEC have low telomerase expression, and therefore do not exhibit tumorigenicity when used \textit{in vivo} [12].

Amniotic mesenchymal cells, show much lower expression of markers for pluripotency than hAEC, and have higher expression of multipotency markers: CD44, CD49e, CD90, and CD105 [109]. Expression of multipotency markers can be observed also in other mesenchymal cells isolated from the afterbirth tissues. Their ability to differentiate into other cells is greater at the early stages of embryonic development and decreases over time. In general, afterbirth's MSC potential to differentiate is higher than suggested by the presence of multipotency or pluripotency markers [110, 111].

\textbf{Table 4} Protocols for \textit{in vitro} differentiation of placental MSC towards hepatocytes, ordered by culture time and cell type. In hepatocyte-like cells obtained after hAM-MSC differentiation, a decreased expression of the alpha-fetoprotein, a marker of fetal hepatocytes, was also observed [111]

| Culture time & surface | Differentiating medium | Gene up-regulation | Increased protein expression | Cell activity | Ref. |
|------------------------|------------------------|--------------------|-----------------------------|--------------|-----|
| human amniotic mesenchymal stromal cells (hAM-MSC) | DMEM/LG, 15% FBS, 20 ng/ml HGF, 10^{-7} M dex, 10 ng/ml OSM, ITS | Not given | AFP, CK18 | Glycogen storage, cellular uptake of indocyanine green | [129] |
| collagen | 1st step: basal medium, 2% FBS, 10 ng/ml bFGF, 20 ng/ml HGF, 0.61 g/L nicotinamide | - | - | - | [111] |
| 2nd step: basal medium, 2% FBS, 1 mM dex, 20 ng/ml OSM, 50 mg/ml ITS+ premix | ALB, CYP3A4 | ALB, HGF | Glycogen storage, cellular uptake of indocyanine green | [111] |
| collagen type-I | α-MEM, 10% FBS, 10 ng/mL hFGF-2, 20 ng/mL hHGF, 0.1 mmol/L dex, 10 ng/mL OSM | A1AT, AFP, CK18, HNF-4α | A1AT, ALB, CK18 | Glycogen storage | [112] |
| human amniotic fluid mesenchymal stem cells (hAF-MSC) | 1st step: IMDM, 10 ng/ml bFGF, 20 ng/ml HGF, 0.1% DMSO | - | - | - | [113] |
| 2nd step: IMDM, 1 M dex, 20 ng/ml OSM, 50 mg/ml ITS+ premix | ALB | Not given | LDL uptake | [113] |
| 4 weeks | 1st step: 60% DMEM, 40% MCDB-201, 2% FBS, 1.623 mM glutamine, 0.03 mM nicotinamide, 1 mg/ml linoleic-acid, 0.1 mM L-ascorbic acid, 0.25 mM sodium pyruvate | - | - | - | [113] |
| collagen type-I | 2nd step: basal medium, 10 ng/ml FGF-4 | AFP, ALB, C/EBPa, CK18, CYP1A1, HNF1-α | Glycogen storage, urea synthesis | [113] |
| 3rd step: basal medium, 20 ng/ml HGF | | | | |
| 4th step: basal medium, 20 ng/ml HGF, 20 mg/l dex, ITS, 1 mM trichostatin A | | | | |
| human chorionic mesenchymal stem cells (hCMSC) | α-MEM, 12% FBS, 2 mM L-glutamine, 10 ng/ml FGF-4, 20 ng/ml HGF, 10^{-7} M dex, 10 ng/ml OSM, ITS, 10 mM N-acetyl-L-cysteine | A1AT, AFP, ALB | A1AT, AFP, ALB | Glycogen storage, cellular uptake of indocyanine green | [112] |
| 3 weeks plastic | | Not given | | [132] |
| collagen | 1st step: basal medium, 2% FBS, 10 ng/ml bFGF, 20 ng/ml HGF, 0.61 g/L nicotinamide | - | - | - | [111] |
| 2nd step: basal medium, 2% FBS, 1 mM dex, 20 ng/ml OSM, 50 mg/ml ITS+ premix | ALB, CYP3A4 | ALB, HGF, SCF | Glycogen storage, cellular uptake of indocyanine green | [111] |
Differentiation of Amniotic Epithelial Cells

Differentiation of hAEC towards functional hepatocytes can be performed by several methods, but the effectiveness of differentiation is difficult to compare between the research centers. Each of the leading research centers determines the degree of cell differentiation in a different way (Table 3). Although, the cells with features of fully mature hepatocytes have not been obtained yet, it has been indicated which one of the many signaling pathways is involved in this process [85].

Summing up publications describing the differentiation of amnion epithelial cells towards hepatocytes, the following conclusions can be made:

- So far, attempts to differentiate epithelial amnion cells have resulted in obtaining cells with features similar to fetal hepatocytes. It was proven based on experimental data of the CYP7A1/CYP3A4 expression ratio [114], and bigger secretion of alpha-fetoprotein over albumin [14, 114].
- Expression of genes characteristic for hepatocyte-like cells obtained in differentiation process is higher than in native hAEC, but definitely lower than in the positive control - HepG2 hepatic cell line [117].
- Culture on plates coated with extracellular matrix promotes hAEC differentiation into hepatocytes [115].

The presence of pluripotency markers, and the expression of genes responsible for differentiation and proliferation make amnion cells similar to induced pluripotent stem cells [118]. This similarity suggests the possibility of differentiating amnion cells with in vitro methods effective for iPSC [119–121]. Adopting effective differentiation protocols seems to be a promising methodological approach for hAEC differentiation [14, 122]. The first stage of this process is iPSC differentiation towards definitive endoderm cells, characterized by increased

### Table 5 Protocols for in vitro differentiation of mesenchymal stem cells isolated from human umbilical cord (hUC-MSC/hWJ-MSC) towards hepatocytes, ordered by culture time

| Culture time & surface | Differentiating medium | Gene up-regulation | Increased protein expression | Cell activity | Ref. |
|------------------------|------------------------|--------------------|-----------------------------|---------------|------|
| 7 days plastic         | liver homogenate supernatant - (150 mg of liver with 1 mL of DMEM/F12) | Not given | AFP, CK18, TPH | CYP3A activity, albumin and urea synthesis | [133] |
| 18 days collagen type-IV | 1st step: low-glucose DMEM, 40% MCDB 201 medium, 2% FBS, 10 ng/ml bFGF, 20 ng/ml HGF | A1AT, ALB, CYP3A4, HNF1-α | Not given | Indocyanine green uptake | | |
|                        | 2nd step: low-glucose DMEM, 40% MCDB 201 medium, 2% FBS, 1 μM dex, 20 ng/ml OSM, ITS+ Premix | ALB, CYP3A4 | ALB, HGF | Glycogen storage, cellular uptake of indocyanine green | | |
| 3 weeks collagen       | 1st step: basal medium, 2% FBS, 10 ng/ml bFGF, 20 ng/ml HGF, 0.61 g/L nicotinamide | ALB, CYP3A4 | ALB, HNF-4α | Glycogen storage, albumin and urea synthesis | | |
|                        | 2nd step: basal medium, 2% FBS, 1 mM dex, 20 ng/ml OSM, 50 ng/ml ITS+ premix | ALB, CYP3A4 | ALB, HNF-4α | Glycogen storage, albumin and urea synthesis | | |
| plastic                | 1st step: ADMEM, 2% FBS, 20 ng/ml HGF | ALB, CK18 | ALB, HNF-4α | Glycogen storage, albumin and urea synthesis | | |
| 4 weeks collagen plastic | 1st step: 5 mM valproic acid | A1AT, A1AT, AFP, ALB, CK18, CYP1A1, CYP3A4, G6P, HNF-4α, TAT | ALB, CYP3A4 | Glycogen storage, albumin and urea synthesis | | |
|                        | 2nd step: 2% FBS, 10 ng/mL FGF-4, 25 ng/mL HGF | A1AT, A1AT, AFP, ALB, CK18, CYP1A1, CYP3A4, G6P, HNF-4α, TAT | ALB, CYP3A4 | Glycogen storage, albumin and urea synthesis | | |
|                        | 3rd step: 2% FBS, 25 ng/mL HGF, 40 mg/mL dex, 20 ng/mL OSM, ITS premix | A1AT, A1AT, AFP, ALB, CK18, CYP1A1, CYP3A4, G6P, HNF-4α, TAT | ALB, CYP3A4 | Glycogen storage, albumin and urea synthesis | | |
|                        | 1st step: IMDM, 10 ng/mL bFGF, 20 ng/mL HGF, 0.61 g/ml nicotinamide | A1AT, AFP, ALB, CYP3A4, G6P, TAT | ALB, CYP3A4 | Glycogen storage, albumin and urea synthesis | | |
|                        | 2nd step: 1 μmol/L dex, 20 ng/mL OSM, 50 mg/ml ITS | A1AT, AFP, ALB, CYP3A4, G6P, TAT | ALB, CYP3A4 | Glycogen storage, albumin and urea synthesis | | |
expression of FOXA2 and SOX17 genes [122, 123]. The following stages are: obtaining hepatoblasts, and their transformation into mature hepatocytes [124]. The cells obtained in this three-step protocol were described as functionally mature hepatocytes, however, different criteria for assessing the obtained cells have been used. Nevertheless, the obtained cells possess secretion, storage, metabolic abilities, and are able to repopulate a damaged liver in animal models [125]. Some preclinical trials have confirmed their usefulness in the treatment of acute liver failure [126] and congenital metabolic disorders associated with impaired protein synthesis [127]. On the other hand, there are concerns about the use of hepatic-like cells (HLC) obtained from iPSC in humans. It is uncertain, if the changes induced in the cell genome would not cause further spontaneous mutations leading to cancer. However, such concerns are not raised by the use of amnion epithelial cells [11] and, as it can be assumed, HLC obtained from them. Preclinical studies on mice [14, 113] using HLC obtained from hAEC have shown, that their use in the treatment of liver failure in humans does not require the use of immunosuppressive treatment [13].

Differentiation of Afterbirth Mesenchymal Cells

Afterbirth mesenchymal cells are an interesting alternative to hAEC for the purpose of hepatocyte differentiation (Tables 4 and 5). A certain limitation of their use on a larger scale is a small number of mesenchymal amniotic cells [109], or mesenchymal umbilical cord cells [128] isolated from one placenta as compared to hAEC [104].

Summing up the studies on differentiation of MSC isolated from afterbirth tissues towards hepatocytes, the following conclusions can be made:

- Media used in the differentiation of hAEC and MSC towards hepatocytes are similar in composition in terms of the growth factors used and their concentrations (Tables 3, 4 and 5). It is yet unknown whether hAEC or MSC have greater differentiation potential towards hepatocytes and this aspect requires further studies.
- Differentiated MSC display hepatocyte-like features in vitro, including urea and albumin synthesis, and CYP3A4 activity proven by proper diazepam and midazolam metabolism, which suggests functionality corresponding to mature hepatocytes [133].
- The differentiation process may be more efficient in afterbirth-derived MSC than in MSC of other origin [111].
- Sequential differentiation without prolonged exposure of MSC to HGF should be more effective than one step differentiation protocols with high concentrations of HGF. It is because prolonged exposure inhibits MSC proliferation and promotes changes in their cytoskeleton [138].
- 3D culture conditions are more effective in the differentiation process of MSC, than standard 2D culture [139].

Preclinical Studies on Using Human Afterbirth Cells and Their Derivatives in Liver Failure Treatment

The potential outcomes of effective cell therapy performed with human stem cells isolated from the afterbirth tissues and their derivatives obtained during its ex vivo differentiation are: their documented potential to reduce inflammation, stimulate cell division, inhibit apoptosis, prevent fibrosis, and undergo further differentiation [105, 140]. A new scientific direction in the area of liver failure therapy are studies on exosomes secreted by stem cells into culture media. Exosomes are molecules other than growth factors, cytokines or hormones. They contain many microRNA, mRNA and protein molecules [141]. In vivo studies demonstrated the effectiveness of exosomes secreted by damaged hepatocytes [141], MSC [142] and hAEC [143] in suppression of toxic liver damage and its hepatoprotective activity.

Preclinical Studies Conducted with hAEC

hAEC were used in the treatment of experimental liver failure in several animal models with native amniotic epithelial cells [144–147], hAEC culture media containing their secretory products [143], and epithelial cells partially differentiated towards human hepatocytes [113]. Each of these approaches has its advantages and limitations, nevertheless, they resulted in improved liver functioning (Table 6). Positive effects of experimental studies and the confirmed safety of amniotic epithelial cells in preclinical studies in vivo, formed the basis for conducting a case-control study in humans in which liver failure was treated with hAEC [11].

Summing up the results of experiments performed in animal models in vivo, it can be stated that hAEC and their derivatives show the following effects in the acute and chronic liver injury:

- hAEC reduce TGFβ synthesis. This leads to inhibition of myofibroblasts derived from HSC, thereby reducing ECM production [145].
- Substances secreted by hAEC into their niche act anti-fibrotically in a paracrine manner [148, 149]. hAECs stimulate the transformation of macrophages into the M2 phenotype, which in contrast to M1, display immunomodulatory, anti-inflammatory and anti-fibrotic activity [143].
- The therapeutic effect of hAEC may be significantly dependent on the number of cells given to the recipient, what should constitute a subject of further studies (Table 6).
Positive effects of hAEC and their derivatives, such as improved liver function, reduction of fibrosis and inflammation, raise the question about the necessity of stem cells differentiation towards hepatocytes, if the use of native amniotic cells gives promising results. Unfortunately, it is not possible to give a clear answer to this question, due to a small number of scientific reports dealing with such cells in *in vivo* therapy.

Lin et al. administered hAEC, partially differentiated towards hepatocytes to mice with chronic liver injury and achieved a greater increase in serum albumin levels in animals, and generally a stronger liver function improvement compared to those that received native amniotic epithelial cells [14]. This indicates, that pre-differentiation towards a specific cell line may result in more effective regeneration and improvement of liver function. A similar phenomenon has been observed in case of preliminary *in vitro* differentiation of mesenchymal stem cells derived from adipose tissue [150], hESC [151] and iPSC [152]. Some researchers remark the aspect of the involvement of mature target organ cells in the *in vivo* differentiation of native hAEC [115, 153].

**Preclinical Studies Conducted with Mesenchymal Stem Cells**

Mesenchymal cell populations isolated from the afterbirth tissues are well characterized in terms of their positive pleiotropic effect in the treatment of liver failure in animals (Tables 7 and 8) and in humans [154, 155].

Attempts have been made to evaluate *in vivo* effects of hepatocyte-like cells derived from afterbirth’s mesenchymal stem cells (Table 9), however this issue requires further studies, ideally comparing the effectiveness of HLC derived from mesenchymal stem cells and native MSC, in the treatment of liver failure.

Summarizing the results of preclinical experiments *in vivo*, the following conclusions can be made regarding the effect of mesenchymal afterbirth cells in acute and chronic liver failure therapy:

- MSC reduce the inflammatory process associated with liver damage by reducing the expression and secretion of inflammatory cytokines. Moreover, they increase the expression and thereby secretion of anti-inflammatory cytokines [156, 175].
- Using MSC in therapy results in limited liver fibrosis [110, 166, 167].
- MSC affect the phenotype of M1 macrophages and promote their change into M2 [175].
- Mesenchymal cells isolated from the postnatal tissues reduce the cytokine storm phenomenon during acute and chronic liver damage, thus reducing the cell apoptosis and necrotic areas [133, 142, 157, 158, 176, 177].

### Table 6: Animal models of the use of hAEC, hAEC-derived hepatocytes and exosomes (EVs) in the treatment of liver failure

| Host                  | Number of cells or EVs per one individual | Experimental model            | Results                                                                 | Ref. |
|-----------------------|------------------------------------------|-------------------------------|------------------------------------------------------------------------|------|
| Native hAEC           |                                          |                               |                                                                        |      |
| Rat 3 × 10⁶           | Acute injury – surgical BDL              | Decreased: fibronectin deposition, areas occupied by myofibroblasts, number of cells positive for S100A4, TGFβ pathway activation, αvβ6 integrin expression. | [145]|
| Mouse 5 × 10⁶         | Acute injury – CCl₄                      | Decreased: levels of total bilirubin, ALAT, ASPAT, ALP; areas of liver necrosis. Increased: survival rate of mouse after lethal dose. | [113]|
| Mouse 4 x 10⁶         | Chronic injury - NAFLD diet              | Decreased: liver fibrosis, activation of HSC, activation of TGFβ pathway, amount and activity of liver parenchymal macrophages. | [144]|
| Mouse 0.5 x 10⁶       | MPS1-knockout (Hurler syndrome)          | Decreased: urinary GAG concentration, increased: liver α-L-iduronidase enzyme activity. General therapeutic efficacy of hAEC for MPS1 Hurler syndrome. | [146]|
| hAEC-derived hepatocytes |                                          |                               |                                                                        |      |
| Mouse 5 × 10⁶         | Acute injury - CCl₄                      | Decreased: levels of total bilirubin, ALAT, ASPAT, ALP; areas of liver necrosis. Increased: survival rate of mice after the lethal dose. | [113]|
| hAEC exosomes         | Mouse 24 × 10⁶ hAEC-EVs                  | Decreased: TGFβ1 and α-SMA expression, collagen production, HSC activation, activation of Kupffer cells and a change in their phenotype. General immunomodulatory and anti-fibrotic effect. | [143]|

- MSC reduce the inflammatory process associated with liver damage by reducing the expression and secretion of inflammatory cytokines. Moreover, they increase the expression and thereby secretion of anti-inflammatory cytokines [156, 175].
- Using MSC in therapy results in limited liver fibrosis [110, 166, 167].
- MSC affect the phenotype of M1 macrophages and promote their change into M2 [175].
- Mesenchymal cells isolated from the postnatal tissues reduce the cytokine storm phenomenon during acute and chronic liver damage, thus reducing the cell apoptosis and necrotic areas [133, 142, 157, 158, 176, 177].
HLC obtained from MSC differentiation under 3D culture conditions are more effective in lowering transaminase levels after in vivo use, than those differentiated under 2D conditions [174].

Hepatocytes derived from MSC improve liver function and increase serum albumin levels more efficiently than native MSC [173].

In vivo use of MSC partially differentiated into hepatocytes appears to be safer than use of native MSC due to the fact that the use of native MSC may result in their differentiation into fibroblasts, which gather in fibrous septa, thus acting profibrotically [172, 178].

Clinical Studies on Epithelial and Mesenchymal Afterbirth Cells in the Treatment of Liver Failure

Based on preclinical attempts to treat liver failure using stem cells isolated from the afterbirth tissues, it can be concluded that these cells support the natural regenerative mechanisms. The use of afterbirth cells is intended to improve liver function, rather than to rebuild its structure. Native cells improve liver function by reducing inflammation and fibrosis, and as a consequence the remaining organ parenchyma has a chance to regenerate itself and regain metabolic function including the

### Table 7

Animal models of the use of mesenchymal stem cells isolated from human umbilical cord (hUC-MSC/hWJ-MSC), their exosomes (EVs) and umbilical cord blood (hUCB-MSC) in the treatment of liver failure

| Host | Number of cells or exosomes per one individual | Experimental model | Results | Ref. |
|------|-----------------------------------------------|--------------------|--------|------|
| human umbilical cord mesenchymal stem cells (hUC-MSC/hWJ-MSC) | | | | |
| Rat  | $5 \times 10^6$ | Dimethyl nitrosamine-induced liver fibrosis | Decreased: ALAT and ASPAT plasma levels, and fibrosis, cholestasis, collagen deposition in the liver; Increased: mobilization of Kupffer cells, transition from M1 to M2 phenotype, and IL-10 and IL-4 plasma levels. | [156] |
|      | $5 \times 10^6$ | Chronic injury – CCl$_4$ | Decreased: expression of α-SMA, TIMP-1, collagen type I and III, and ALAT, ASPAT and plasma bilirubin levels; hepatocyte swelling, necrosis, steatosis and centers of regeneration; Increased: expression of vimentin, E-cadherin, α-catenin and MMP-13, and ALB concentration. | [157] |
|      | $3 \times 10^6$ | Ischaemia/reperfusion (I/R) injury | Decreased: ALAT, ASPAT, ALP, IL-1β, IL-6, and TNFα in plasma, hepatocyte necrosis, number of hepatic infiltrating neutrophils, expression of caspase 3 and mitochondrial reactive oxygen species levels, serum IL-1β, IL-6, and TNFα levels (all in both groups - hUC-MSC-treated and hUC-MSC-EVs-treated) | [142] |
|      | 2.85-3mg | hUC-MSC-EVs | | |
|      | 2.2-2.5 x $10^6$ | Acute injury - D-GaIN (1000 mg/kg b.w.) and LPS (10μg/kg b.w.) | Decreased: ALAT, ASPAT and bilirubin in plasma, hepatocyte necrosis and inflammation, number of apoptotic hepatocytes; Increased: number of proliferating hepatocytes. | [158] |
|      | 1 x $10^6$ | Acute injury – CCl$_4$ | Decreased: ALAT, ASPAT and bilirubin levels in plasma, inflammation, cell degeneration and necrosis. | [133] |
| Mouse | $5 \times 10^6$ | Acute injury - acetaminofen i.p. 500mg/kg b.w. | Decreased: ALAT, ASPAT, ALP, GGTP and bilirubin in plasma, interstitial inflammation. | [159] |
|      | 3-5 x $10^6$ | Acute injury - CCl$_4$ | Decreased: ALAT, ASPAT bilirubin levels. | [160] |
|      | 2 x $10^6$ | Chronic injury – CCl$_4$ | Decreased: mRNA expression, inflammation and swelling of liver cells, damage to mitochondria and parenchyma; Increased: TGFα mRNA expression. | [161] |
|      | 1 x $10^6$ | Ischaemia/reperfusion (I/R) injury | Decreased: ALAT and ASPAT in plasma, severity of damage. | [162] |
|      | 5 x $10^5$ | Fulminant injury – D-GaIN | Decreased: number of necrotic cells and inflammatory response cells, reduced liver damage, extended survival time of animals. | [163] |
|      | 2.5 x $10^5$ | Acute injury – CCl$_4$ | ALAT, MCP-1 and IP-10 serum levels were not significantly changed indicating lack of therapeutic effect of stem cells. | [164] |
| human umbilical cord blood mesenchymal stem cells (hUCB-MSC) | | | | |
| Mouse | $1 \times 10^6$ | Chronic injury – CCl$_4$ | Decreased: bilirubin level, expression of ITGB1 and COL1A1, number of SMA(+) cells and parenchymal fibrosis; Increased: albumin synthesis. | [165] |
synthesis of proteins. However, the use of native cells resulted in lesser improvement compared to partially differentiated cells. Positive results and the lack of side effects of the use of native hAEC in preclinical studies of liver failure therapy resulted in their introduction into human studies. First stages of clinical trials were carried out on patients in the terminal stage of chronic liver failure. They aimed at the assessment of safety of native hAEC, but not epithelial cells differentiated into hepatocytes, in therapy of liver diseases in humans, but their results have not yet been published [11, 13].

Over the last decade, the interest in mesenchymal cells has increased significantly, and the total number of registered clinical trials using native hAM-MSC, hAF-MSC, hWJ-MSC, hCP-MSC, hCV-MSC and hUC-MSC in the

| Table 8 | Animal models of the use of mesenchymal stem cells isolated from human placenta in the treatment of liver failure |
|---------|---------------------------------------------------------------|
| Host | Number of cells or exosomes per one individual | Experimental model | Results | Ref. |
|---------------------------------------------------------------|
| human amniotic mesenchymal stromal cells (hAM-MSC) | | | | |
| Rat | $1 \times 10^6$ | Sclerosing cholangitis, ANIT-induced | Decreased: biliary hyperplasia, fewer necrotic changes, expression of MMP-9, α-SMA, TGF-β, type I collagen, MMP-2 and TIMP-1, Glisson score. | [166] |
| | | Chronic injury – CCl₄ induced | Decreased: expression of COL1, α-SMA, CD68 and TIMP-1; increased: expression of MMP-9 and HGF. General anti-fibrotic effect. | [167] |
| Mouse | intrahepatic administration, number not given | Acute injury - CCl₄ induced | Decreased: ALAT, ASPAT, TNF and IFN-γ plasma levels, histological markers of liver damage; increased: IL-10 plasma concentration. | [168] |
| human chorionic plate mesenchymal stem cells (hCP-MSC) | | | | |
| Rat | $2 \times 10^6$ | Chronic injury - CCl₄ induced | Decreased: expression of Shh, Smo, Gli2 and Gli3 (HH signaling pathway), amount of hepatic hydroxyproline, number of collagen fibers and liver progenitor cells; increased: expression of Ihh protein and miRNA-125b. Decreased: IL-6 and IL-6 receptor methylation; increased: expression of cyclins E and A, albumin, and IL-6; methylation of SOCS3 and STAT3. Decreased: lymphocyte infiltration, expression of PARP, caspase 3/7, proteins of the pathway associated with autophagy (PI3K class III, Beclin1, ATG7, ATG5-12, and LC3 II), and phosphorylated m-TOR kinase; increased: HIF-1α expression and its translocation to the nucleus, protein expression of Bcl-2, Bax, factors associated with proliferation (Jak1, PI3K p110α, phosphorylated ERK1/2, and Smad2/3), cyclin E and A, PTTG1, IL-6, gp130, ABCG1 and ABCG2, and proliferation index (Ki67). | [169] [170] [171] |

| Table 9 | Animal models of the use of hepatocyte-like cells derived from human umbilical cord and umbilical cord blood in the treatment of liver failure |
|---------|---------------------------------------------------------------|
| Host | Number of HLCs per one individual | Experimental model | Results | Ref. |
|---------------------------------------------------------------|
| human umbilical cord-derived hepatocyte-like cells | | | | |
| Rat | $1 \times 10^6$ | Acute injury - CCl₄ | Decreased: bilirubin, ALAT and ASPAT serum levels, reduced liver damage; increased: serum albumin level. survival rate of rats after lethal dose. | [172] |
| Mouse | | | | |
| human umbilical cord blood-derived hepatocyte-like cells | | | | |
| Mouse | $1 \times 10^6$ | Chronic injury – CCl₄ | Decreased: ALAT and ASPAT plasma levels, fibrotic index. Reduced liver damage. | [174] |
treatment of various diseases, exceeded 100 [75]. According to the U.S. National Library of Medicine database, 20 clinical trials using hUC-MSC are registered for the treatment of liver diseases, including 15 in cirrhosis (as of 12/03/2020). In the study of Xu et al., hUC-MSC (1 x 10^6 cells/kg b.w. twice or four times, depending on the group) were administered to patients with acute hepatic failure overlapping chronic failure caused by HBV infection. The decrease in ALAT, ASPAT and bilirubin in plasma, as well as in MELD score, was observed [154]. In the pilot study of Shi et al., patients after liver transplantation with acute transplant rejection received hUC-MSC (1 x 10^6 cells/kg b.w.) together with standard immunosuppression. Patients after hUC-MSC infusion had lower ALAT plasma levels, and increased levels of the TGFβ1 and PGE2, in comparison to the control group. Moreover, improved liver morphology and a higher number of regulatory T lymphocytes in peripheral blood, were observed. No side effects of stem cell infusions were identified [179]. Zhang et al. examined the effects of hUC-MSC in patients with decompensated cirrhosis in the course of chronic hepatitis B. Patients received 0.5 x 10^6 cells/kg b.w. and were followed up for two years after administration. Increased levels of plasma albumin, prothrombin and cholinesterase, together with reduced total bilirubin level were observed in patients in the study group. The authors concluded about possible improvements in liver function and thrombin functionality in these patients. The decrease in the MELD Na score was faster in the patients in the study group, and a significant reduction in ascites was observed. The concentration of liver fibrosis markers (serum laminin, hyaluronic acid, PIINP and type IV collagen) decreased and HGF level (fibrosis inhibiting factor) increased compared to the control group [155]. Unfortunately, trials using afterbirth MSC other than hUC-MSC or MSC partially differentiated into hepatic cells are not registered for the treatment of liver diseases [75].

### Summary

Previous in vitro and in vivo studies indicate that cells isolated from the afterbirth tissues may play an important role in the supportive therapy for acute and chronic liver failure. Their advantages include multilineage potential for differentiation, no need for immunosuppression after administration, and no tumor formation in recipient organisms [147, 180]. The heterogeneous population of these cells comprises the cells of different stages of differentiation, namely: pluripotent, multipotent, progenitor, and mature cells, characterized by the expression of specific transcription factors and surface markers [181]. The expression of epithelial, or mesenchymal markers, as well as lineage-associated markers of early differentiation, varies among hAEC and afterbirth MSC reflecting their potential to proliferation, self-renewal, and differentiation towards the cells representing three germ lineages. Both hAEC and MSC express embryonic stem cell and pluripotency markers, however the level of marker expression remains variable. Furthermore, hAEC express epithelial cell markers such as cytokeratins, E-cadherin, and EpCAM. In turn, mesenchymal cell markers are more specific to afterbirth MSC but they have also been reported on the surface of hAEC [182, 183]. A very small amount or none of the studied hAEC and afterbirth MSC express hematopoietic markers. However, both these populations express various endodermal markers, as GATA-4, HNF-3β, AFP, ALB (in hAEC), GLUT-2, CK18, A1AT, and HNF-4α. After the culture of amnion cells with the hepatic differentiation protocol, they expressed high mRNA levels of both fetal and adult hepatocyte markers: AFP, CYP7A1, ALB, and A1AT [85]. It should be noted, that there are discrepancies in the data presented by authors in the literature concerning the pattern of markers expressed by epithelial and mesenchymal afterbirth cells [109, 181].

Native human afterbirth cells share some phenotypic features comparable with human hepatic multipotent stem cells (hHpSC) and bipotent hepatoblasts: EpCAM, CK19, CD133 [17, 27, 35, 181], adult multipotent stem cells expressing mesenchymal markers: CD44, CD73, CD90, CD105, CK19, SSEA-4, NANOOG, OCT-4 [15, 52, 66, 67, 181, 53–60] and adult bipotent hepatic progenitor cells (HPC): DLK-1 [78, 184]. EpCAM expression, characteristic of hepatoblasts, but not of mesenchymal liver cells, has been confirmed in afterbirth cells only in few studies [181, 183–185].

Experimental data indicate that stem cell pre-differentiation towards a specific cell line may result in more effective regeneration and improvement of liver function [14]. So far, attempts to differentiate afterbirth cells toward hepatocytes resulted in obtaining cells with features of hepatoblasts, characterized by elevated expression of fetal hepatocyte-specific genes (Fig. 1). It is yet unknown whether hAEC or afterbirth MSC have greater hepatocytic differentiation potential. It cannot be excluded that the differentiation process may be more efficient in afterbirth-derived MSC than in MSC of other origins. Sequential differentiation without prolonged exposure of MSC to HGF should be more effective than one step differentiation protocols with high concentrations of HGF. Culturing the afterbirth cells on plates coated with extracellular matrix or 3D culture conditions promote differentiation into hepatocytes. A similar phenomenon of enhanced liver regeneration by pre-differentiated stem cells [14] has been observed during preliminary in vitro differentiation of adipose tissue-derived mesenchymal stem cells, hESC, and iPSC [126]. Perhaps the use of a three-step differentiation protocol for the differentiation of the fetal MSC and/or hAEC will result in fully functional hepatocytes, as has been described earlier in iPSC cultures [122].
Preclinical trials using the native afterbirth MSC and hAEC resulted in improved liver function in animals, and the cells given became similar to hepatocytes over time, thus, to some extent, restored its structure [180]. Afterbirth cells reduced the inflammatory process associated with liver damage by inhibiting the production of inflammatory cytokines and secretion of anti-inflammatory cytokines, thus reducing the cell apoptosis and necrotic areas, and inhibited liver fibrosis [145, 156, 175].

Positive effects observed in animals led to clinical trials in humans. In the case of native hUC-MSC, beneficial effects on liver function were observed, whereas results of the use of native hAEC are yet unknown [11, 13].

The use of pre-differentiated human liver cells in preclinical studies resulted in noticeably better improvement in liver function, compared to the native cells [14]. However, the protocols for in vitro obtaining hepatocytes from afterbirth stem cells are not optimized and require further improvements and subsequent evaluation of the usefulness of these cells in in vivo liver regeneration models. To date, no clinical trial using hepatocyte-like cells obtained by differentiation of afterbirth cells, based on effective, safe, and GMP-compliant protocol cells, has been registered.

Acknowledgements This work was supported by Polish Ministry of Science and Higher Education, Diamond Grant 0034/DIA/2018/47 (M. Michalik).

Author Contributions Concept, design, writing original draft, review & editing: Marcin Michalik, Aleksandra Gładys, Piotr Czekaj

Funding This work was supported by Polish Ministry of Science and Higher Education, Diamond Grant 0034/DIA/2018/47 (M. Michalik).
Compliance with Ethical Standards

Conflict of Interest The authors declare no conflict of interest.

Human and Animal Rights This paper is a review article, therefore the study does not involve human participants or animals

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Adam, R., Karam, V., Cailliez, V. O., Grady, J. G., Mirza, D., Cherqui, D., Klemmepauer, J., Salizzoni, M., Pratschke, J., Jamieson, N., Hidalgo, E., Paul, A., Lopez Andujar, R., Lerut, J., Fisher, L., Boudjemma, K., Fondevalia, C., Soubrane, O., Bachelier, P., Pinna, A. D., Berlakovich, G., Bennet, W., Pinzani, M., Schemmer, P., Zieniewicz, K., Jimenez Romero, C., De Simone, P., Ericzon, B., Schneeberger, S., Wigmore, S. J., Fabregat Prous, J., Colledan, M., Porte, R. J., Yilmaz, S., Azoulay, D., Pirenne, J., Line, P., Truneca, P., Navarro, F., Valdivieso Lopez, A., De Carlis, L., Rufian Pena, S., Kochs, E., & Duvoix, C. (2018). 2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transplant International, 31(12), 1293–1317. https://doi.org/10.1111/tri.13588.

2. Kubota, T., Hata, K., Sozua, T., Ueda, Y., Hiroa, H., Okamura, Y., Tamaki, T., Yoshikawa, J., Kusakabe, J., Tanaka, H., Kageyama, S., Anazawa, T., Yoshizawa, A., Yagi, S., Yamashiki, N., Okajima, H., Kaido, T., & Uemoto, S. (2018). Impact of donor age on recipient survival in adult-to-adult living-donor liver transplantation. Annals of Surgery, 267(6), 1126–1133. https://doi.org/10.1097/SLA.0000000000002194.

3. Emre, S., & Unman, V. (2011). Split liver transplantation: an overview. Transplantation Proceedings, 43(3), 884–887. https://doi.org/10.1016/j.transproced.2011.02.036.

4. Gilgenkrantz, H., & Collin de l’Hortet, A. (2018). Understanding liver regeneration: from mechanisms to regenerative medicine. American Journal of Pathology, 188(6), 1316–1327. https://doi.org/10.1016/j.ajpath.2018.03.008.

5. Iansante, V., Mitry, R. R., Filippi, C., Fitzpatrick, E., & Dhawan, A. (2018). Human hepatocyte transplantation for liver disease: current status and future perspectives. Pediatric Research, 83(1–2), 232–240. https://doi.org/10.1038/pr.2017.284.

6. Hu, J., Yu, X., Wang, Z., Wang, F., Wang, L., Gao, H., Chen, Y., Zhao, W., Jia, Z., Yan, S., & Wang, Y. (2013). Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocrine Journal, 60(3), 347–357. https://doi.org/10.1507/endocr.JE12-0343.

7. Wang, D., Feng, X., Lu, L., Konkel, J. E., Zhang, H., Chen, Z., Li, X., Gao, X., Lu, L., Shi, S., Chen, W., & Sun, L. (2014). A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arthritis and Rheumatology, 66(8), 2234–2245. https://doi.org/10.1002/art.38674.

8. Liang, J., & Sun, L. (2015). Mesenchymal stem cells transplantation for systemic lupus erythematosus. International Journal of Rheumatic Diseases, 18(2), 164–171. https://doi.org/10.1111/1756-185X.12531.

9. Wu, X., Xia, Y., Zhou, O., Song, Y., Zhang, X., Tian, D., Li, Q., Shu, C., Liu, E., Yuan, X., He, L., Liu, C., Li, J., Liang, X., Yang, K., Fu, Z., Zou, L., Bao, L., & Dai, J. (2020). Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (MSC-BPD trial). Trials, 21(1), 1–10. https://doi.org/10.1186/s13063-019-3935-x.

10. Phan, T. G., Ma, H., Lim, R., Sobey, C. G., & Wallace, E. M. (2018). Phase 1 trial of amnion cell therapy for ischemic stroke. Frontiers in Neurology, 9(JUN), 1–7. https://doi.org/10.3389/fneur.2018.00198.

11. Lim, R., Hodge, A., Moore, G., Wallace, E. M., & Sievert, W. (2017). A pilot study evaluating the safety of intravenously administered human amnion epithelial cells for the treatment of hepatic fibrosis. Frontiers in Pharmacology, 8(AUG), 1–9. https://doi.org/10.3389/fphar.2017.00549.

12. Strom, S. C., & Gramignoli, R. (2016). Human amnion epithelial cells expressing HLA-G as novel cell-based treatment for liver disease. Human Immunology, 77(9), 734–739. https://doi.org/10.1016/j.jhimmun.2016.07.002.

13. Gramignoli, R., Morandi, F., Horenstein, A., Strunz, B., Srinivasan, R. C., Malavasi, F., & Strom, S. C. (2019). Cellular mechanism in support of allogeneic human amnion epithelial cell transplantation without immunosuppression. Cytotherapy, 21(5), S26. https://doi.org/10.1016/j.jcyt.2019.03.335.

14. Lin, J. S., Zhou, L., Sagayara, A., Jumat, N. H. B., Choolani, M., Chan, J. K. Y., Biswas, A., Wong, P. C., Lim, S. G., & Dan, Y. Y. (2015). Hepatic differentiation of human amniotic epithelial cells and in vivo therapeutic effect on animal model of cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 30(11), 1673–1682. https://doi.org/10.1111/jgh.12991.

15. Kholodenko, I. V., Kurbatov, L. K., Kholodenko, R. V., Manukyan, G. V., & Yarinyin, K. N. (2019). Mesenchymal stem cells in the adult human liver: hype or hope? Cells, 8(10), 1–37. https://doi.org/10.3390/cells8101127.

16. Tanimizu, N., & Mitaka, T. (2014). Re-evaluation of liver stem / progenitor cells. Organogenesis, 10(2), 208–215.

17. Schmelzer, E. (2019). Hepatic progenitors of the fetal liver: interactions with hematopoietic stem cells. Differentiation, 106(Feb), 9–14. https://doi.org/10.1016/j.diff.2019.02.005.

18. Katoonizadeh, A. (2017). Liver regeneration. Liver pathophysiology: Therapies and antioxidants. Elsevier Inc. https://doi.org/10.1016/B978-0-12-804274-8.00007-2.

19. Ko, S., Russell, J. O., Molina, L. M., & Monga, S. P. (2020). Liver progenitors and adult cell plasticity in hepatic injury and repair: knowns and unknowns. Annual Review of Pathology: Mechanisms of Disease, 15, 23–50. https://doi.org/10.1146/annualrev-pathmechdis-012419-032824.

20. Yang, L., Li, L. C., Lameaqiezhang, Wang, X., Wang, W. H., Wang, Y. C., & Xu, C. R. (2019). The contributions of mesoderm-derived cells in liver development. Seminars in Cell and Developmental Biology, 92(August 2018), 63–76. https://doi.org/10.1016/j.semcdb.2018.09.003.

21. Treff, E., Gannon, M., & Wasserman, D. H. (2017). The liver. Current Biology, 27(21), R1147–R1151. https://doi.org/10.1016/j.cub.2017.09.019.
50. Avila, M. A., & Moschetta, A. (2015). The FXR-FGF19 gut-liver axis as a novel “hepatostat”. *Gastroenterology*, 149(3), 537–540. https://doi.org/10.1053/j.gastro.2015.07.029.

51. Michalopoulous, G. K. (2014). Advances in liver regeneration. *Expert Review of Gastroenterology and Hepatology*, 8(8), 897–907. https://doi.org/10.1586/17447142.2014.934358.

52. Herrera, M. B., Bruno, S., Buttiglieri, S., Tetta, C., Gatti, S., Deregibus, M. C., Bussolati, B., & Camussi, G. (2006). Isolation and characterization of a stem cell population from adult human liver. *Stem Cells*, 24(12), 2840–2850. https://doi.org/10.1634/stemcells.2006-0114.

53. Navarro-Tableros, V., Herrera Sanchez, M. B., Figliolini, F., Romagnoli, R., Tetta, C., & Camussi, G. (2015). Recellularization of rat liver scaffolds by human liver stem cells. *Tissue Engineering - Part A*, 21(11–12), 1929–1939. https://doi.org/10.1089/ten.tea.2014.0573.

54. Bruno, S., Grange, C., Tapparo, M., Pasquino, C., Romagnoli, R., Dametto, E., Amoroso, A., Tetta, C., & Camussi, G. (2016). Human liver stem cells suppress T-cell proliferation, NK activity, and dendritic cell differentiation. *Stem Cells International*, 2016. https://doi.org/10.1155/2016/8468549.

55. Herrera, M. B., Fonsato, V., Bruno, S., Grange, C., Gilbo, N., Romagnoli, R., Tetta, C., & Camussi, G. (2013). Human liver stem cells improve liver injury in a model of fulminant liver failure. *Hepatology*, 57(1), 311–319. https://doi.org/10.1002/hep.25986.

56. Navarro-Tableros, V., Gai, C., Gomez, Y., Giunti, S., Pasquino, C., Deregibus, M. C., Tapparo, M., Pitino, A., Tetta, C., Brizzi, M. F., Ricordi, C., & Camussi, G. (2019). Islet-like structures generated in vitro from adult human liver stem cells revert hyperglycemia in diabetic SCID mice. *Stem Cells Reviews and Reports*, 15(1), 93–111. https://doi.org/10.1007/s12978-018-9845-6.

57. Bruno, S., Herrera Sanchez, M. B., Pasquino, C., Tapparo, M., Cedrino, M., Tetta, C., & Camussi, G. (2019). Human liver-derived stem cells improve fibrosis and inflammation associated with nonalcoholic steatohepatitis. *Stem Cells International*, 2019. https://doi.org/10.1155/2019/6351091.

58. Lopatina, T., Grange, C., Fonsato, V., Tapparo, M., Brossa, A., Fallo, S., Pitino, A., Herrera-Sanchez, M. B., Kholia, S., Camussi, G., & Bussolati, B. (2019). Extracellular vesicles from human liver stem cells inhibit tumor angiogenesis. *International Journal of Cancer*, 144(2), 322–333. https://doi.org/10.1002/ijc.31796.

59. Spada, M., Porta, F., Righi, D., Gazzera, C., Tandoi, F., Ferrero, I., Fagioli, F., Herrera Sanchez, M. B., Calvo, P. G., Biamino, E., Bruno, S., Gunetti, M., Contursi, C., Lauritano, C., Conio, A., Amoroso, A., Salizzoni, M., Silengo, L., Camussi, G., & Romagnoli, R. (2020). Intrahepatic administration of human liver stem cells in infants with inherited neonatal-onset hyperammonemia: a phase I study. *Stem Cell Reviews and Reports*, 16(1), 186–197. https://doi.org/10.1007/s12978-019-00925-z.

60. Famulari, E. S., Navarro-Tableros, V., Herrera Sanchez, M. B., Bortolussi, G., Gai, M., Conti, L., Silengo, L., Tolosano, E., Tetta, C., Muro, A. F., Camussi, G., Fagoonee, S., & Altruda, F. (2020). Human liver stem cells express UGT1A1 and improve phenotype of immunocompromised Crigler Najjar syndrome type 1 mice. *Scientific Reports*, 10(1), 1–14. https://doi.org/10.1038/s41598-020-57820-2.

61. Lee, J. H., Park, H. J., Kim, Y. A., Lee, D. H., Noh, J. K., Kwon, C. H. D., Jung, S. M., & Lee, S. K. (2012). Differentiation and major histocompatibility complex antigen expression in human liver-derived stem cells. *Transplantation Proceedings*, 44(4), 1113–1115. https://doi.org/10.1016/j.transproceed.2012.03.008.

62. Lee, J. H., Park, H. J., Kim, Y. A., Lee, D. H., Noh, J. K., Kwon, C. H. D., Jung, S. M., & Lee, S. K. (2012). The phenotypic characteristic of liver-derived stem cells from adult human deceased donor liver. *Transplantation Proceedings*, 44(4), 1110–1112. https://doi.org/10.1016/j.transproceed.2012.02.020.

63. Lee, J. H., Park, H. J., Jang, I. K., Kim, H. E., Lee, D. H., Park, J. K., Lee, S. K., & Yoon, H. H. (2014). In vitro differentiation of human liver-derived stem cells with mesenchymal characteristics into immature hepatocyte-like cells. *Transplantation Proceedings*, 46(5), 1633–1637. https://doi.org/10.1016/j.transproceed.2013.12.070.

64. Najimi, M., Khuu, D. N., Lysy, P. A., Jazouli, N., Abarca, J., Sempoux, C., & Sokal, E. M. (2007). Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? *Cell Transplantation*, 16(7), 717–728. https://doi.org/10.3727/000000007783465154.
74. Fonsato, V., De Lena, M., Trittia, S., Brossa, A., Calvetti, R., Tetta, C., Camussi, G., & Bussolati, B. (2018). Human liver stem cell-derived extracellular vesicles enhance cancer stem cell sensitivity to tyrosine kinase inhibitors through Akt/mTOR/PEN combined modulation. *Oncotarget*, 9(90), 36151–36165. https://doi.org/10.18632/oncotarget.26319.

75. U.S. National Library of Medicine. (2020). Retrieved August 12, 2020, from www.clinicaltrials.gov

76. Abdellatif, H. (2018). Oval cells: potential role in liver regeneration. *Biomedical Journal of Scientific & Technical Research*, 2(1). https://doi.org/10.26717/bjstjr.2018.02.000665.

77. Fausto, N., & Campbell, J. S. (2003). The role of hepatocytes and oval cells in liver regeneration and repopulation. *Mechanisms of Development*, 120(1), 117–130. https://doi.org/10.1016/s0925-4773(02)00338-6.

78. Shin, S., & Kaestner, K. H. (2014). The origin, biology, and therapeutic potential of facultative adult hepatic progenitor cells. *Current Topics in Developmental Biology*, 107, 269–292. https://doi.org/10.1016/B978-0-12-416022-4.00100-X.

79. Czajka, P. (2004). Molecular and cellular mechanisms of chemically induced hepatocarcinogenesis. *Polish Journal of Environmental Studies*, 13(5), 477–486.

80. Tanaka, M., & Miyajima, A. (2016). Liver regeneration and fibrogenesis during their hepatic differentiation. *C. L.*. https://doi.org/10.1371/journal.pone.0191489.

81. Maymó, J. L., Riedel, R., Pérez-Pérez, A., Magatti, M., Maskin, T., Tsuchiya, A., & Yu, W. (2019). Liver stem cells: plasticity of the hepatocyte-like cell in liver regeneration. *Acta Histochemica*, 119(4), 349–356. https://doi.org/10.1016/j.acthis.2017.03.006.

82. Tarlow, B. D., Pelz, C. N., Wakefield, W. E. L., Elizabeth, M., Finegold, M. J., & Grompe, M. (2014). Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. *Cell Stem Cell*, 15(5), 605–618. https://doi.org/10.1016/j.stem.2014.09.008.

83. Tsuchiya, A., & Yu, W. (2019). Liver stem cells: plasticity of the hepatocyte-like cell in liver regeneration. *Acta Histochemica*, 119(4), 349–356. https://doi.org/10.1016/j.acthis.2017.03.006.

84. Grompe, M. (2014). Liver stem cells, where art thou? *Cell Stem Cell*, 15(3), 257–258. https://doi.org/10.1016/j.stem.2014.08.004.

85. Ji, H., Lu, Y., & Shi, Y. (2017). Seeds in the liver. *Acta Histochemica*, 119(4), 349–356. https://doi.org/10.1016/j.acthis.2017.03.006.

86. Hongcui, C., & Li, L. (2013). Human hepatic progenitor cells express hematopoietic cell markers CD45 and CD109. *International Journal of Medical Sciences*, 11(1), 65–79. https://doi.org/10.7150/ijms.7426.

87. Tanaka, M., & Miyajima, A. (2016). Liver regeneration and fibrogenesis during their hepatic differentiation. *C. L.*. https://doi.org/10.1371/journal.pone.0191489.

88. López-Navarrete, G., Ramos-Martínez, E., Suárez-Álvarez, K., Gudiño-Zayas, M., Guzmán, C., Gutiérrez-Reyes, G., Hernández-Ruíz, J., Camacho-Arroyo, I., Robles-Díaz, G., Gutiérrez-Reyes, G., & Pérez-Pérez, A. (2016). Distinct role of interleukin-6 and tumor necrosis factor receptor-1 in oval cell-mediated liver regeneration and inflammation and regeneration, 36(1), 1–6. https://doi.org/10.1186/s41232-016-0025-2.

89. Fabregat, I., Moreno-Ciceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., & ten Dijke, P. (2016). TGF-β signaling and liver disease. *FEBS Journal*, 2219–2232. https://doi.org/10.1111/febs.13665.

90. Chen, Y. G., Lui, H. M., Lin, S. L., Lee, J. M., & Ying, S. Y. (2002). Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. *Experimental Biology and Medicine*, 227(2), 75–87. https://doi.org/10.1177/1537302022700201.

91. Chen, J., Tschudy-Seney, B., Ma, X., Zou, M. A., Liu, P., & Duan, Y. (2018). Salvianolic acid B enhances hepatic differentiation of human embryonic stem cells through upregulation of WNT pathway and inhibition of Notch pathway. *Stem Cells and Development*, 27(4), 252–261. https://doi.org/10.1089/scd.2017.0168.

92. Han, Y. J., Kang, Y. H., Shivakumar, S. B., Bharti, D., Son, Y. B., Choi, Y. H., Park, W. U., Byun, J. H., Rho, G. J., & Park, B. W. (2017). Stem cells from cryopreserved human dental pulp tissues sequentially differentiate into definitive endoderm and hepatocyte-like cells in vitro. *International Journal of Medical Sciences*, 14(3), 1418–1429. https://doi.org/10.7150/ijms.22152.

93. Kim, H. J., Cho, Y. A., Lee, Y. M., Lee, S. Y., Bae, W. J., & Kim, E. C. (2016). PIN1 suppresses the hepatic differentiation of human embryonic stem cells towards hepatocytes. *Nature Communications*, 8(May), 1–12. https://doi.org/10.1038/ncomms15166.

94. Fabregat, I., Moreno-Ciceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., & ten Dijke, P. (2016). TGF-β signaling and liver disease. *FEBS Journal*, 2219–2232. https://doi.org/10.1111/febs.13665.

95. Chen, Y. G., Lui, H. M., Lin, S. L., Lee, J. M., & Ying, S. Y. (2002). Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. *Experimental Biology and Medicine*, 227(2), 75–87. https://doi.org/10.1177/1537302022700201.

96. Chen, J., Tschudy-Seney, B., Ma, X., Zou, M. A., Liu, P., & Duan, Y. (2018). Salvianolic acid B enhances hepatic differentiation of human embryonic stem cells through upregulation of WNT pathway and inhibition of Notch pathway. *Stem Cells and Development*, 27(4), 252–261. https://doi.org/10.1089/scd.2017.0168.

97. Li, Q., Hutchins, A. P., Chen, Y., Li, S., Shan, Y., Liao, B., Zheng, D., Shi, X., Li, Y., Chan, W., Pan, G., Wei, S., Shu, X., & Pei, D. (2017). A sequential EMT-MET mechanism drives the differentiation of human embryonic stem cells towards hepatocytes. *Nature Communications*, 8(May), 1–12. https://doi.org/10.1038/ncomms15166.

98. Fabregat, I., Moreno-Ciceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., & ten Dijke, P. (2016). TGF-β signaling and liver disease. *FEBS Journal*, 2219–2232. https://doi.org/10.1111/febs.13665.

99. Fabregat, I., Moreno-Ciceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., & ten Dijke, P. (2016). TGF-β signaling and liver disease. *FEBS Journal*, 2219–2232. https://doi.org/10.1111/febs.13665.
104. Gramignoli, R., Srinivasan, R. C., Kannisto, K., & Strom, S. C. (2016). Isolation of human amnion epithelial cells according to current good manufacturing procedures. Current Protocols in Stem Cell Biology, 2016, 1E.10.1–1E.10.13. https://doi.org/10.1002/cpsc.2.

105. Kolanko, E., Kopaczka, K., Koryciak-Komarska, H., Czech, E., Szmytkowska, P., Gramignoli, R., & Czekaj, P. (2019). Increased immunomodulatory capacity of human amniotic cells after activation by pro-inflammatory chemokines. European Journal of Pharmacology, 859(April), 172545. https://doi.org/10.1016/j.ejphar.2019.172545.

106. Szmytkowska, P., Koryciak-Komarska, H., Limanowska, L., Król, M., Płewka, D., Kopaczka, K., & Czekaj, P. (2019). Comparison on efficiency of various enzymatic methods for the isolation of cells from human amnion. In Advances in biomedical research. From microbiology to cancer (pp. 99–109). Lublin: Tygiet, Warszawa: Warszawski Uniwersytet Medycyny.

107. García-Castro, I. L., García-López, G., Ávila-González, D., Flores-Herrera, H., Molina-Hernández, A., Portillo, W., Ramón-Gallegos, E., & Díaz, N. F. (2015). Markers of pluripotency in human amniotic epithelial cells and their differentiation to progenitor of cortical neurons. PLoS ONE, 10(12), 1–18. https://doi.org/10.1371/journal.pone.0146082.

108. Parolini, O., Alviano, F., Bagnara, G. P., Bilic, G., Bühring, H.-J., Evangelista, M., Hennerichbel, S., Liu, B., Magatti, M., Mao, N., Miki, T., Marongiu, F., Nakajima, H., Nikaido, T., Portmann-Lanz, C. B., Sankar, V., Soncini, M., Stadler, G., Surbek, D., Takahashi, T. A., Redl, H., Sakuragawa, N., Wolbank, S., Zeisberger, S., Zisch, A., & Strom, S. C. (2008). Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells. Stem Cells, 26(2), 300–311. https://doi.org/10.1634/stemcells.2007-0594.

109. Bilic, G., Zeisberger, S. M., Mallik, A. S., Zimmermann, R., & Zisch, A. H. (2008). Comparative characterization of cultured human term amnion epithelial and mesenchymal stromal cells for application in cell therapy. Cell Transplantation, 17(8), 955–968. https://doi.org/10.3727/096368908x865765070.

110. Kim, E. Y., Lee, K. B., & Kim, M. K. (2014). The potential of mesenchymal stem cells derived from amniotic membrane and amniotic fluid for neuronal regenerative therapy. BMB Reports, 47(3), 135–140. https://doi.org/10.5483/BMBRep.2014.47.3.289.

111. Lee, H. J., Jung, J., Cho, K. J., Lee, C. K., Hwang, S. G., & Kim, G. J. (2012). Comparison of in vitro hepatogenic differentiation potential between various placenta-derived stem cells and other adult stem cells as an alternative source of functional hepatocytes. Differentiation, 84(3), 223–231. https://doi.org/10.1016/j.jdiff.2012.05.007.

112. Tamagawa, T., Oi, S., Ishiwata, I., Ishikawa, H., & Nakamura, Y. (2007). Differentiation of mesenchymal stem cells derived from human amniotic membranes into hepatocyte-like cells in vitro. Human Cell, 20(3), 77–84. https://doi.org/10.1111/j.1749-0774.2007.00032.x.

113. Liu, Q. W., Liu, Q. Y., Li, J. Y., Wei, L., Ren, K. K., Zhang, X. C., Ding, T., Xiao, L., Zhang, W. J., Wu, H. Y., & Xin, H. B. (2018). Therapeutic efficiency of human amniotic epithelial stem cells-derived functional hepatocyte-like cells in mice with acute hepatic failure. Stem Cell Research and Therapy, 9(1), 1–15. https://doi.org/10.1186/s13287-018-1063-2.

114. Miki, T., Marongiu, F., Ellis, E. C. S., Dorko, K., Mitamura, K., Ranade, A., Gramignoli, R., Davila, J., & Strom, S. C. (2009). Production of hepatocyte-like cells from human amnion. In Hepatocyte transplantation (Vol. 481, pp. 155–168). https://doi.org/10.1007/978-1-59745-201-4_13.

115. Marongiu, F., Gramignoli, R., Dorko, K., Miki, T., Ranade, A. R., Serra, M. P., Doratiotti, S., Sini, M., Shamma, S., Mitamura, K., Sellaro, T. L., Tahan, V., Skvorak, K. J., Ellis, E. C. S., Badylak, S. F., Davila, J. C., Hines, R., Laconi, E., & Strom, S. C. (2011). Hepatic differentiation of amniotic epithelial cells. Hepatology, 53(5), 1719–1729. https://doi.org/10.1002/hep.24255.

116. Vaghihi, V., Vaitilingam, V., Saraswati, I., Sali, A., Murthi, P., Kallioniis, B., Tuch, B. E., & Manoyalpilai, U. (2014). Hepatocyte-like cells derived from human amniotic epithelial cells can be encapsulated without loss of viability or function in vitro. Stem Cells and Development, 23(8), 866–876. https://doi.org/10.1089/scd.2013.0485.

117. Lee, H. J., Jung, J., Cho, K. J., Lee, C. K., Hwang, S. G., & Kim, M. K. (2014). Engraftment of human induced pluripotent stem cell-derived hepatocytes in immunocompetent mice via 3D co-aggregation and encapsulation. Scientific Reports, 5(April), 1–13. https://doi.org/10.1038/srep16884.

118. Xia, Y., Carpentier, A., Cheng, X., Block, P. D., Zhao, Y., Zhang, Z., Proctor, U., & Liang, T. J. (2017). Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. Journal of Hepatology, 66(3), 494–503. https://doi.org/10.1016/j.jhep.2016.10.009.

119. Song, W., Lu, Y. C., Frankel, A. S., An, D., Schwartz, R. E., & Ma, M. (2015). Production of hepatocyte-like cells derived from human amniotic epithelial and mesenchymal stromal cells using small molecules. Differentiation of hepatocyte-like cells from human pluripotent stem cell derived hepatocytes in immunocompetent mice as via 3D co-aggregation and encapsulation. Stem Cell Research, 16(3), 640–650. https://doi.org/10.1016/j.scr.2016.03.009.

120. Tasiim, F., Phan, D., Toh, Y. C., & Yu, H. (2015). Cost-effective differentiation of hepatocyte-like cells from human pluripotent stem cells using small molecules. Biomaterials (Vol. 70). Elsevier Ltd. https://doi.org/10.1016/j.biomaterials.2015.08.002.

121. Palakkan, A. A., Nanda, J., & Ross, J. A. (2017). Pluripotent stem cells to hepatocytes, the journey so far. Biomedical Reports, 6(4), 367–373. https://doi.org/10.3892/br.2017.867.

122. Hannoun, Z., Steichen, C., Dianat, N., Weber, A., & Dubart-Kupperschmitt, A. (2016). The potential of induced pluripotent stem cell derived hepatocytes. Journal of Hepatology, 65(1), 182–199. https://doi.org/10.1016/j.jhep.2016.02.025.

123. Takayama, K., Akita, N., Mimura, N., Akahira, R., Taniguchi, Y., Ikeda, M., Sakurai, F., Ohara, O., Morio, T., Sekiguchi, K., & Mizuguchi, H. (2017). Generation of safe and therapeutically effective human induced pluripotent stem cell-derived hepatocyte-like cells for regenerative medicine. Hepatology Communications, 1(10), 1028–1069. https://doi.org/10.1002/hep3.1111.

124. Okamoto, R., Takayama, K., Akita, N., Nagamoto, Y., Hosokawa, D., Iizuka, S., Sakurai, F., Suemizu, H., Ohashi, K., & Mizuguchi, H. (2018). Human iPS cell-derived liver-like tissue engineering at extrahepatic sites in mice as a new cell therapy for hemophilia B. Cell Transplantation, 27(2), 299–309. https://doi.org/10.1177/096369717751734.

125. Han, Y. F., Tao, R., Sun, T. J., Chai, J. K., Xu, G., & Liu, J. (2013). Optimization of human umbilical cord mesenchymal stem cell
cells in chemically defined conditions. Cell Death and Disease, 10(10). https://doi.org/10.1038/s41419-019-1967-5.

152. Balasiddaiah, A., Moreno, D., Guembe, L., Prieto, J., & Alldabe, R. (2013). Hepatic differentiation of mouse iPSCs and analysis of liver engraftment potential of multistage iPSC progeny. Journal of Physiology and Biochemistry, 69(4), 835–845. https://doi.org/10.1007/s13105-013-0260-9.

153. Maraldi, T., Bertoni, L., Riccio, M., Zavatti, M., Carnevale, G., Resca, E., Guida, M., Beretti, F., La Sala, G. B., & De Pol, A. (2014). Human amniotic fluid stem cells: neural differentiation in vitro and in vivo. Cell and Tissue Research, 357(1), 1–13. https://doi.org/10.1007/s00441-014-1840-x.

154. Xu, W. Z., He, H. L., Pan, S. W., Chen, Y. L., Zhang, M. L., Zhu, S., Gao, Z. L., Peng, L., & Li, J. G. (2019). Combination treatments of plasma exchange and umbilical cord-derived mesenchymal stem cell transplantation for patients with hepatitis B virus-related acute-on-chronic liver failure: a clinical trial in China. Stem Cells International, 2019. https://doi.org/10.1155/2019/4130757.

155. Zhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Li, Y., Yu, S., Geng, H., Jin, L., Lau, G. K., & Wang, F. S. (2012). Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. Journal of Gastroenterology and Hepatology (Australia), 27(SUPPL.2), 112–120. https://doi.org/10.1111/j.1440-1746.2011.07024.x.

156. Chai, N. L., Zhang, X. B., Chen, S. W., Fan, K. X., & Linghu, E. Q. (2016). Umbilical cord-derived mesenchymal stem cells alleviate liver fibrosis in rats. World Journal of Gastroenterology, 22(26), 6036–6048. https://doi.org/10.3748/wjg.v22.i26.6036.

157. Zhang, G. Z., Sun, H. C., Zheng, L. B., Guo, J. B., & Zhang, X. L. (2017). In vivo hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: therapeutic effect on liver fibrosis/cirrhosis. World Journal of Gastroenterology, 23(46), 8152–8168. https://doi.org/10.3748/wjg.v23.i46.8152.

158. Zhang, Y., Li, Y., Li, W., Cai, J., Yue, M., Jiang, L., Xu, R., Zhang, L., Li, J., & Zhu, C. (2018). Therapeutic effect of human umbilical cord mesenchymal stem cells at various passages on acute liver failure in rats. Stem Cells International, 2018. https://doi.org/10.1155/2018/7159465.

159. Chetty, S. S., Praneetha, S., Govarthanan, K., Verma, R. S., & Sakamoto, N. (2018). Effects of human amnion-derived mesenchymal stem cells and conditioned medium in rats with sclerosing cholangitis. American Journal of Translational Research, 10(7), 2102–2114.

160. Kubo, K., Ohnishi, S., Hosono, H., Fukai, M., Kameya, A., Higashi, R., Yamada, T., Onishi, R., Yamahara, K., Takeda, H., & Sakamoto, N. (2015). Human amnion-derived mesenchymal stem cell transplantation ameliorates liver fibrosis in rats. Transplantation Direct, 1(4), 1–9. https://doi.org/10.1097/txd.0000000000000525.

161. Zagoura, D., Trohatou, O., Makridakis, M., Kollia, A., Kokla, N., Mokou, M., Psaraki, A., Eliopoulos, A. G., Vlahou, A., & Roubelakis, M. G. (2019). Functional secretome analysis reveals Annexin-A1 as important paracrine factor derived from fetal mesenchymal stem cells in hepatic regeneration. EBioMedicine, 45, 542–552. https://doi.org/10.1016/j.ebiom.2019.07.009.

162. Hyun, J., Wang, S., Kim, J., Kim, G. J., & Jung, Y. (2015). MicroRNA125b-mediated Hedgehog signaling influences liver regeneration by chorionic plate-derived mesenchymal stem cells. Scientific Reports, 5(May), 1–15. https://doi.org/10.1038/srep14135.

163. Jung, J., Moon, J. W., Choi, J. H., Lee, Y. W., Park, S. H., & Kim, G. J. (2015). Epigenetic alterations of IL-6/STAT3 signaling by placental stem cells promote hepatic regeneration in a rat model with CCl4-induced liver injury. International Journal of Stem Cells, 8(1), 79–89. https://doi.org/10.15283/ijsc.2015.8.1.79.

164. Jung, J., Choi, J. H., Lee, Y., Park, J. W., Oh, I. H., Hwang, S. G., Kim, K. S., & Kim, G. J. (2013). Human placenta-derived mesenchymal stem cells promote hepatic regeneration in CCl4-injured rat liver model via increased autophagic mechanism. Stem Cells, 31(8), 1584–1596. https://doi.org/10.1002/stem.1396.

165. Kao, S., Shyu, J., Wang, H., Hsiao, C., Su, C., Chen, T., & Weng, Z. (2016). Transplantation of hepatocyte-like cells derived from umbilical cord stromal mesenchymal stem cells to treat acute liver failure rat abstract. Journal of Biomedical Sciences, 7(1:2), 1–9. https://doi.org/10.4172/2254-609X.10002.

166. Cui, L., Shi, Y., Zhou, X., Wang, X., Wang, J., Lan, Y., Wang, M., Zheng, L., Li, H., Wu, Q., Zhang, J., Fan, D., & Han, Y. (2013). A set of microRNAs mediate direct conversion of human umbilical cord lining-derived mesenchymal stem cells to treat acute liver failure rat abstract. Journal of Biomedical Sciences, 7(1:2), 1–9. https://doi.org/10.4172/2254-609X.10002.

167. El Baz, H., Demerdash, Z., Kamel, M., Hammod, O., Samir Abdelhady, D., Mahmoud, S., Hassan, S., Mahmoud, F., Atta, S., Riad, N. M., & Gaafar, T. (2020). Induction of hepatic regeneration in an experimental model using hepatocyte-differentiated mesenchymal stem cells. Cellular Reprogramming, 22, 1–13. https://doi.org/10.1089/cell.2019.0076.

168. Eom, Y. W., Shim, K. Y., & Baik, S. K. (2015). Mesenchymal stem cell therapy for liver fibrosis. The Korean Journal of Internal
176. Guo, G., Zhuang, X., Xu, Q., Wu, Z., Zhu, Y., Zhou, Y., Li, Y., Lu, Y., Zhang, B., Talbot, P., Liao, J., She, J., Bu, H., & Shi, Y. (2019). Peripheral infusion of human umbilical cord mesenchymal stem cells rescues acute liver failure lethality in monkeys. Stem Cell Research and Therapy, 10(1), 1–13. https://doi.org/10.1186/s13287-019-1184-2.

177. Tsuchiya, A., Takeuchi, S., Watanabe, T., Yoshida, T., Nojiri, S., Ogawa, M., & Terai, S. (2019). Mesenchymal stem cell therapies for liver cirrhosis: MSCs as "conducting cells" for improvement of liver fibrosis and regeneration. Inflammation and Regeneration, 39(1), 4–9. https://doi.org/10.1186/s41232-019-0107-z.

178. Valfrè Di Bonzo, L., Ferrero, I., Cravanzola, C., Mareschi, K., Rustichelli, D., Novo, E., Sanavio, F., Cannito, S., Zamara, E., Bertero, M., Davit, A., Francica, S., Novelli, F., Colombatto, S., Fagioli, F., & Parola, M. (2008). Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut, 57(2), 223–231. https://doi.org/10.1136/gut.2006.111617.

179. Shi, M., Liu, Z., Wang, Y., Xu, R., Sun, Y., Zhang, M., Yu, X., Wang, H., Meng, L., Su, H., Jin, L., & Wang, F. S. (2017). A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. Stem Cells Translational Medicine, 6(12), 2053–2061. https://doi.org/10.1002/scit.20134.

180. Gramignoli, R. (2016). Therapeutic use of human amnion-derived products: cell-based therapy for liver disease. Current Pathobiology Reports, 4(3), 157–167. https://doi.org/10.1007/s40139-016-0112-8.

181. Ghamari, S. H., Abbasi-Kangevari, M., Tayebi, T., Bahrami, S., & Niknejad, H. (2020). The bottlenecks in translating placenta-derived amniotic epithelial and mesenchymal stromal cells into the clinic: current discrepancies in marker reports. Frontiers in Bioengineering and Biotechnology, 8(March), 1–13. https://doi.org/10.3389/fbioe.2020.00180.

182. Koike, C., Zhou, K., Takeda, Y., Fathy, M., Okabe, M., Yoshida, T., Nakamura, Y., Kato, Y., & Nikaido, T. (2014). Characterization of amniotic stem cells. Cellular Reprogramming, 16(4), 298–305. https://doi.org/10.1089/cell.2013.0090.

183. Topoluk, N., Hawkins, R., Tokish, J., & Mercuri, J. (2017). Amniotic mesenchymal stromal cells exhibit preferential osteogenic and chondrogenic differentiation and enhanced matrix production compared with adipose mesenchymal stromal cells. The American Journal of Sports Medicine, 45(11), 2637–2646. https://doi.org/10.1177/0363546517706138.

184. Srinivasan, R. C., Strom, S. C., & Gramignoli, R. (2020). Effects of cryogenic storage on human amnion epithelial cells. Cells, 9(7), 1–13. https://doi.org/10.3390/cells9071696.

185. Pratama, G., Vaghjiani, V., Tee, J. Y., Liu, Y. H., Chan, J., Tan, C., Murthi, P., Gargett, C., & Manuelpillai, U. (2011). Changes in culture expanded human amniotic epithelial cells: implications for potential therapeutic applications. PLoS ONE, 6(11). https://doi.org/10.1371/journal.pone.0026136.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.